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1	Summary	
	Self-renewal	and	differentiation	are	the	two	key	properties	that	characterize	stem	cells.	 To	 initiate	 differentiation,	 pluripotent	 embryonic	 stem	 cells	 (ESC)	must	 be	forced	 out	 of	 self-renewal,	 the	 transcriptional	 networks	 conferring	 stem	 cell	identity	need	to	be	dissolved	and	lineages	must	be	chosen.	Compared	to	acquisition	and	maintenance	of	ESCs	pluripotency,	the	mechanisms	driving	exit	from	this	cell	state	are	ill	defined.	Previous	work	has	identified	the	tumor	suppressor	Folliculin	(Flcn)	as	a	novel	gene	required	for	exit	 from	the	ESC	state	during	differentiation	(Betschinger	et	al.,	2013a).	Flcn	loss	of	function	in	mice	is	early	embryonic	lethal	consistent	with	being	required	for	exit	from	pluripotency	in	vivo.	It	has	been	shown	in	 ESCs	 that	 Flcn	 and	 two	 associated	 proteins,	 Fnip1	 and	 Fnip2,	 regulate	 the	subcellular	 localization	 of	 the	 basic	 helix-loop-helix	 transcription	 factor	 Tfe3.	 In	wildtype	ESCs,	Tfe3	 is	ubiquitously	detected	 in	the	nucleus	and	cytoplasm.	Upon	ESC	differentiation,	Tfe3	is	excluded	from	the	nucleus	whereas	Flcn	loss	of	function	ESCs	 harbor	 constitutive	 nuclear	 Tfe3	 localization	 and	 are,	 consequentially,	impaired	in	differentiation.	Consistently,	ectopic	nuclear	Tfe3	similarly	inhibits	ESC	differentiation.	Recently,	Flcn	has	been	identified	in	a	metabolic	pathway	leading	to	the	activation	of	the	mTORC1	complex	in	an	amino-acid	sensing	dependent	manner	after	 nutrient	 starvation	 (Tsun	 et	 al.,	 2013).	 However,	 mTORC1	 activity	 is	 not	required	for	ESC	differentiation.	To	gain	insights	into	the	regulation	of	this	process,	we	conducted	a	genome-wide	CRISPR/Cas9	screen	in	ESCs	that	aimed	to	identify	genes	that,	similar	to	Flcn,	are	required	 for	 the	maintenance	 of	 stem	 cell	 identity	 upon	 long	 term	 exposure	 to	differentiation	 stimuli.	 Although	 molecularly	 related	 to	 amino-acid	 sensing	dependent	mTORC1	regulation,	our	 findings	suggest	an	alternate	mode	of	action	that	may	be	founded	in	the	non-starving	nature	of	ESC	differentiation.	In	addition,	we	show	in	ESC	that	the	lysosome	regulates	the	assembly	of	a	Flcn-Tfe3	axis,	whose	impairment	induces	an	embryonic	developmental	arrest.	Additionally,	in	a	collaborative	work	with	human	geneticists,	we	identified	five	Tfe3	point	 mutations	 in	 a	 human	 syndrome	 called	 hypomelanosis	 of	 Ito.	 Symptoms	associated	with	this	developmental	disorder	include	severe	intellectual	disability,	
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coarse	 facial	 features,	 frontonasal	 dysplasia,	 obesity,	 epilepsy	 and	 growth	retardation,	 suggesting	a	pleiotropic	developmental	disorder.	To	understand	 the	developmental	nature	of	 the	disease,	we	 tested	 these	mutations	 in	ESCs	 and	we	found	 them	 causing	 defects	 in	 exit	 from	 self-renewal	 and	 nuclear	 Tfe3	accumulation.		Taken	together,	the	work	presented	in	this	thesis	has	allowed	the	identification	of	the	 lysosome	 as	 a	 critical	 organelle	 required	 for	 the	 control	 of	 the	 exit	 from	pluripotency	and	 indicates	 that	 lysosomal	 recruitment	of	Tfe3	 is	 required	 for	 its	inactivation,	which	is	a	crucial	step	to	enable	normal	developmental	progression.	
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2	Introduction		2.1	Murine	embryonic	stem	cells		
2.1.1	Origin	of	ESCs			 In	mammals,	embryos	develop	from	the	fusion	of	a	sperm	cell	and	the	oocyte,	two	very	specialized	cell	types.	After	fertilization,	the	newly	created	zygote	grows	up	to	a	very	dense	cellular	sphere	and	eventually	compacts	to	reach	the	early	blastocyst	stage	at	embryonic	day	(E)	3.5.	At	this	stage,	the	blastocyst	is	a	layer	of	epithelial	cells,	 the	 trophectoderm,	 encapsulating	 the	 inner	 cell	 mass	 (ICM).	 Murine	pluripotent	embryonic	stem	cells	(ESCs)	are	derived	from	the	mid-blastocyst-stage	embryo	between	E	3.75	and	E	4.5.	At	this	stage,	the	ICM	segregates	into	epiblast	and	hypoblast	and	ESCs	derivation	in	vitro	pauses	developmental	progression	from	the	epiblast.	ESCs	can	differentiate	in	vitro	into	all	cell	types	of	the	embryo	as	well	as	in	
vivo	 when	 transplanted	 back	 into	 the	 blastocyst.	 This	 unique	 feature	 of	 ESCs	recapitulates	 the	 pluripotency	 of	 the	 pre-implantation	 epiblast.	 Upon	developmental	progression	in	vivo	when	the	embryo	implants	into	the	uterine	wall	(E	5.5),	or	upon	differentiation	in	vitro,	pluripotency	potential	decreases	rapidly.	In	fact,	ESCs	self-renew	indefinitely	in	vitro	while	pluripotency	exists	only	transiently	
in	vivo.	ESCs	display	unique	properties	that	make	them	attractive	for	regenerative	medicine	and	in-depth	characterization	will	help	to	facilitate	their	manipulation	in	
vitro.			
2.1.2	Maintenance	of	the	ground	state	of	pluripotency		Originally	ESCs	were	directly	isolated	from	the	late	blastocyst	and	were	maintained	in	 culture	 in	 vitro	 on	 a	 feeder	 layer	 of	 mitotically	 inactivated	 fibroblasts	 in	 the	presence	of	serum,	allowing	ESCs	to	proliferate	without	losing	their	pluripotency,	which	is	called	self-renewal	 	((Evans	and	Kaufman,	1981);	(Martin,	1981)).	Early	studies	have	 shown	 that	 feeder	 cells	 secrete	Leukemia	 Inhibitory	Factor	 (LIF),	 a	cytokine	promoting	the	maintenance	of	pluripotency	(Smith	et	al.,	1988).	Therefore,	the	feeders	have	been	replaced	by	addition	of	LIF	directly	in	the	culture	medium.	Furthermore,	 bone	 morphogenic	 protein	 4	 (BMP4)	 was	 identified	 as	 the	 key	
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inhibitor	 of	 differentiation	present	 in	 the	 serum.	A	 fine	balance	between	 stimuli	promoting	 self-renewal	 and	 stimuli	 inhibiting	 differentiation	 regulates	 the	maintenance	of	the	stem	cell	pool	and	needs	to	be	tightly	controlled	when	cells	are	cultured	in	vitro.	ESCs	grown	in	Serum/LIF	condition	give	rise	to	a	heterogeneous	cell	population	of	cells	in	formative	pluripotent	state	that	corresponds	to	the	peri-implantation	 stage	 in	 vivo.	 Naïve	 and	 primed	 pluripotent	 stem	 cells	 display	 key	differences	in	their	derivation	of	germline-competent	PSCs,	epigenomic	states,	gene	expression	 of	 naïve	 pluripotency	 markers	 and	 lineage-specific	 genes,	 signaling	requirements	to	maintain	self-renewal,	and	central	carbon	metabolism	(Davidson	et	 al.,	 2015).	Over	 the	past	decade,	 genetic	 screens	have	helped	 to	 identify	 gene	regulatory	 networks	 governing	 ESC	 identity	 and	 enabled	 the	 development	 of	modulators	 targeting	 specific	 signaling	 pathways	 involved	 in	 pluripotency	regulation.	 In	particular,	modulation	of	both	Wnt	and	the	Fgf	signaling	pathways	resulted	in	a	more	homogenous	ESC	culture	as	compared	to	culture	in	the	presence	of	serum	and	LIF.	Mechanistically,	Chiron	(CHIR99021),	a	glycogen	synthase	kinase	3	 (GSK3)	 inhibitor	 and	 thus	Wnt	 signaling	 activator,	 promotes	 the	 pluripotency	gene	 network	 therefore	 enhancing	 the	 self-renewal	 ability	 of	 ESCs.	 In	 contrast,	PD03	 (PD0325901)	 impairs	 the	 initiation	 of	 differentiation	 by	 inhibiting	 Fgf	signaling	(Figure1).	Altogether,	this	formed	the	basis	for	the	formulation	of	culture	conditions	required	for	the	maintenance	of	a	homogenous	population	of	ESCs	in	the	ground	state	of	pluripotency	in	vitro,	so	called	2i/LIF	(Ying	et	al.,	2008).					
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Figure	1:	Signaling	pathways	promoting	pluripotency	and	inhibiting	differentiation		Schematic	representation	of	pathways	activated	in	the	presence	of	serum	and	LIF	in	the	culture	medium	(serum/LIF	condition	-	left	part)	or	in	the	presence	of	2	inhibitors,	Chiron	and	PDO3	(2i	conditions	–	right	part).	Both	conditions	result	in	the	maintenance	of	a	pluripotent	state	in	
vitro.	 Present	 in	 the	 serum,	BMP4	activates	 the	 SMAD	signaling	 cascade,	 upstream	of	 the	 Id	proteins	 that	 inhibit	differentiation.	Activation	of	 the	 JAK/STAT	signaling	pathway	by	LIF	 in	ESCs	 leads	 to	 activation	 of	 Tcfp2l1	 and	 Klf4,	 key	 transcription	 factors	 of	 the	 pluripotency	network.	Inhibition	of	GSK3	by	Chiron	mimics	canonical	Wnt	signaling	leading	to	stabilization	of	 beta-catenin	 which	 consequently	 binds	 TCF3	 and	 inhibits	 the	 repression	 of	 Esrrb	 gene	maintaining	sustained	activation	of	pluripotency.	MAPK	pathway	is	activated	by	FGF	signaling,	leading	 to	 phosphorylation	 of	 MEK	 and	 activation	 of	 ERK	 which	 in	 turn	 promotes	 ESC	differentiation	that	is	blocked	in	the	presence	of	PDO3.	Figure	taken	from	(Hackett	and	Surani,	2014).			An	established	core	network	of	 transcription	 factors	secures	 the	ground	state	of	pluripotency	 that	 is	 rapidly	 transcriptionally	 down-regulated	 after	 initiation	 of	differentiation	and	therefore	allowed	to	monitor	the	loss	of	stem	cell	identity	during	ESC	differentiation.			
2.1.3	Exit	from	the	ground	state	of	pluripotency			Self-renewal	 confers	 to	 ESCs	 the	 unique	 ability	 to	 proliferate	 without	differentiation.	 To	 initiate	 differentiation,	 ESCs	 must	 be	 forced-out	 of	 the	 self-renewing	state,	the	transcriptional	networks	conferring	stem	cell	identity	need	to	be	 dissolved	 and	 lineages	 have	 to	 be	 governed.	 Compared	 to	 acquisition	 and	maintenance	of	ESC	pluripotency,	the	mechanisms	driving	exit	from	this	cell	state	
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are	ill	defined.	Upon	exposure	to	appropriate	stimuli,	in	vitro	cultured	ESCs	initiate	differentiation	 programs	which	 recapitulate	 the	 developmental	 progression	 that	occurs	 in	 vivo	 (Buecker	 et	 al.,	 2014).	 Traditionally,	 exit	 from	 pluripotency	 was	considered	 to	 be	 a	 unidirectional	 process	 in	 which	 a	 stem	 or	 a	 progenitor	 cell	differentiate	to	give	rise	to	a	specialized	cell	type	with	a	defined	function.		However,	this	process	can	be	reverted	and	fibroblast	reprogramming	towards	an	induced	pluripotent	stem	cell	state	was	rendered	possible	chemically	or	genetically	by	overexpression	of	pluripotency	genes	called	the	Yamanaka’s	factors	(Zhu	et	al.,	2010)	 (Takahashi	 and	 Yamanaka,	 2006).	 Nonetheless,	 how	 exit	 from	 the	pluripotent	state	is	regulated	remains	poorly	understood.	In	order	to	get	a	better	understanding	 of	 this	 process,	 different	 approaches	 have	 attempted	 to	 identify	genes	 whose	 absence	 would	 impair	 ESCs	 differentiation.	 Numerous	 unbiased	genome-wide	 loss-of-function	 genetic	 screens	 have	 identified	 several	 genes	important	for	the	exit	of	pluripotency	and	did	contribute	to	a	better	understanding	of	stem	cell	identity	((Betschinger	et	al.,	2013);	(Yang	et	al.,	2012);	(Westerman	et	al.,	2011);	(Leeb	et	al.,	2014)).	These	include	known	components	of	the	Fgf	and	Wnt	signaling	pathways.					2.2	Metabolic	control	of	cell	fate	transition				
2.2.1	Glycolysis	as	a	predominant	pathway	for	energy	production	in	ESCs			During	embryonic	development,	 after	morula	 compaction,	naïve	ESCs	within	 the	ICM	of	the	pre-implantation	epiblast	rely	on	oxidative	phosphorylation	(OxPhos)	as	their	primary	source	of	energy.	After	implantation,	ESCs	from	the	post-implantation	epiblast	display	a	strong	 increase	 in	the	metabolic	 flux	and	a	high	glycolytic	rate	even	when	cultured	outside	of	the	hypoxic	blastocyst	environment.	The	naïve-to-primed	 transition	 is	 accompanied	 by	 an	 intrinsic	 reduction	 of	 OxPhos	 and	 an	increased	 rate	of	 glycolysis	due	 to	down-regulation	of	 the	 cytochrome	c	oxidase	(COX)	genes	and	high	expression	of	glucose	transporters,	respectively	((Sperber	et	al.,	 2015),	 (Zhang	et	 al.,	 2016)).	Whether	 the	metabolic	 switch	observed	 in	 vitro	reflects	the	 in	vivo	situation	remains	controversial.	Most	of	the	stem	cells	rely	on	
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anaerobic	glycolysis	in	their	original	compartment	called	the	stem	cell	niche	(e.g.	hematopoietic	 stem	 cells)	 but	 contrary	 to	 adult	 stem	 cells	 that	 are	 quiescent,	pluripotent	ESCs	are	highly	proliferative	(Ito	and	Suda,	2014).	From	an	energetic	aspect,	glycolysis	offers	numerous	advantages	including	minimizing	the	production	of	 reactive	 oxygen	 species	 (ROS)	which	 cause	 oxidative	 damages.	 Also,	 the	 high	glycolytic	 rate	 of	 ESCs	 allows	 for	 fast	 energy	 production,	 generation	 of	 anabolic	intermediates	as	well	as	nucleotide	production	via	the	pentose	phosphate	pathway.	During	 ESC	 differentiation,	 the	 mitochondria	 undergo	 maturation	 and	 develop	cristae	 structures	 within	 their	 inner	 membrane	 which	 is	 accompanied	 by	 an	increase	 in	 their	 membrane	 potential	 but	 not	 reflected	 in	 an	 increase	 in	mitochondrial	 respiration	 ((Van	 Blerkom,	 2009);	 (Zhou	 et	 al.,	 2012)).	 These	changes	 accompany	 the	 metabolic	 shift	 from	 oxidative	 glycolysis	 toward	mitochondrial	 oxidative	 phosphorylation.	 The	 hypoxia	 inducible	 factor	 1	 alpha	(Hif1a)	 transcription	 factor	described	to	be	activated	 in	response	 to	hypoxia	has	been	described	to	induce	a	switch	from	bivalent	to	exclusive	glycolytic	metabolism	during	ESC-to-EpiSC	transition	(Zhou	et	al.,	2012).	This	metabolic	shift	has	often	been	compared	to	the	Warburg	effect	described	in	cancer	 cells	 that	orchestrates	a	metabolic	 rewiring	 towards	high	glycolytic	 rates	instead	of	oxidative	phosphorylation	for	energy	production	(Vander	Heiden	et	al.,	2009).	This	hypothesis	has	been	discarded	and	it	is	considered	that	high	glycolytic	rates	 are	 a	 common	 feature	 of	 rapidly	 dividing	 cells	 (Moussaieff	 et	 al.,	 2015).	However,	 the	 metabolic	 shift	 toward	 anaerobic	 glycolysis	 after	 the	 blastocyst	implantation	 into	 the	 uterine	wall	 remains	 unproven	 ((Barbehenn	 et	 al.,	 1978);	(Brinster	and	Troike,	1979)).	Like	 any	 other	 cell	 types,	 ESCs	 sense	 their	 environment	 and	 regulate	 their	metabolism	 accordingly.	 During	 reprogramming	 of	 somatic	 cells	 toward	pluripotent	stem	cells,	a	metabolic	switch	occurs	at	early	stages	of	this	process.	It	is	therefore	conceivable	that	a	metabolic	checkpoint	is	activated	before	ESCs	undergo	differentiation	since	this	cellular	process	requires	a	large	amount	of	energy.	In	line	with	 this	 hypothesis,	 dysregulation	 of	 metabolic	 pathways	 or	 perturbations	 of	metabolite	concentrations	per	se	could	impair	ESCs	differentiation,	recapitulating	a	delay	of	developmental	progression	in	vivo.			
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2.2.2	Metabolic	control	of	pluripotency			ESCs	are	very	proliferative	and	retain	their	self-renewal	property	upon	cell	division,	maintaining	the	ESC	pool.	The	predominant	dependency	of	ESCs	on	glycolysis	is	a	unique	characteristic	of	their	pluripotent	state	which	stands	in	contrast	to	somatic	cells	that	rely	essentially	on	mitochondrial	oxidative	phosphorylation	(OxPhos)	for	energy	production.		These	observations	have	raised	a	lot	of	attention	and	recent	studies	have	directly	linked	metabolism	to	the	regulation	of	the	stem	cell	state	(Sperber	et	al.,	2015).	For	example,	successful	reprogramming	of	somatic	cells	towards	induced	pluripotent	stem	cells	(iPSCs)	is	always	accompanied	by	a	metabolic	shift	characterized	by	an	upregulation	of	glycolysis	which	occurs	even	before	the	acquisition	of	pluripotency	(Folmes	et	al.,	2011).		This	 strongly	 supports	 the	 importance	of	metabolic	 control	of	 stem	cell	 identity.	OxPhos	takes	place	within	the	cristae	of	mature	mitochondria	through	the	electron	transport	chain.	One	of	the	functions	of	OxPhos	is	to	regenerate	NAD+	in	order	to	keep	 active	 the	 TCA	 cycle.	 This	 is	 crucial	 to	 generate	 sufficient	 levels	 of	 alpha	ketoglutarate	which	is	required	for	epigenetic	modifier	functions	like	demethylases	(Carey	 et	 al.,	 2014).	An	 intrinsic	metabolic	 control	 of	 pluripotency	 also	 exists	 in	cultured	 ESCs.	 LIF-induced	 STAT3	 activation	 as	 well	 as	 Esrrb,	 can	 promote	 the	transcription	of	mitochondrial	genes	which	in	turn	regulate	transcription	of	genes	required	for	mitochondrial	Oxphos	reaction	(Carbognin	et	al.,	2016);		in	line	with	this	finding,	the	transcription	factor	Hif1a	was	shown	to	control	the	activity	of	the	gene	Esrrb	(Zhou	et	al.,	2012).		Glutamine	has	also	been	linked	to	stem	cell	regulation.	In	addition	to	contributing	to	 the	 alpha	 ketoglutarate	 pool,	 glutamine	 controls	 cellular	 redox	 reactions.	 A	recent	study	has	linked	glutamine	metabolism	to	the	regulation	of	pluripotency	in	human	 ESCs	 by	 maintaining	 high	 levels	 of	 the	 transcription	 factor	 Oct4	 in	 its	reduced	form,	allowing	its	binding	to	DNA	(Marsboom	et	al.,	2016).	In	this	study,	glutamine	 removal	 from	 the	 medium	 decreased	 the	 pool	 of	 the	 endogenous	antioxidant	gluthatione	(GSH)	leading	to	Oct4	degradation,	demonstrating	its	direct	involvement	in	controlling	pluripotency.	
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In	addition,	ESCs	are	highly	dependent	on	threonine	metabolism	that	ensures	the	regeneration	 of	 the	 S-adenosyl	 methionine	 (SAM)	 pool,	 which	 is	 required	 as	 a	cofactor	 for	 certain	 post-translational	 modifications	 including	 the	 repressive	histone	mark	H3K27me3.	This	illustrates	a	tight	link	between	metabolic	regulation	of	gene	expression	and	the	control	of	stem	cell	identity.			
2.2.3	mTOR	signaling	pathway	is	activated	during	ESC	differentiation		The	 mammalian	 target	 of	 rapamycin	 complex	 (mTORC)	 is	 a	 serine/threonine	protein	kinase,	a	master	regulator	of	cellular	growth.	mTOR	belongs	to	the	family	of	phosphoinositide-3-kinase-related	 kinases.	 mTORC	 kinase	 promotes	 growth	 in	response	to	a	large	diversity	of	signaling	molecules	such	as	growth	factors	and	its	activity	 is	 regulated	 at	 different	 levels	 by	 cellular	 stresses	 including	 variation	 in	energy	levels.	Two	mTORC	complexes	do	exist,	namely	mTORC1	and	mTORC2,	that	share	 the	 same	 catalytic	 sub-unit	 called	 mTOR;	 however,	 mTORC1	 remains	 the	more	 characterized.	 mTORC1	 is	 regulated	 by	 two	 distinct	 mechanisms;	 on	 one	hand,	growth	factors	signal	through	the	Tsc1/2-Rheb	axis	(reviewed	in	(Laplante	and	 Sabatini,	 2009))	 whereas	 amino-	 acids	 are	 sensed	 and	 signal	 through	 the	Ragulator	protein	complex	localized	at	the	lysosomal	surface	(Zoncu	et	al.,	2011)	(see	 section	 1.3.2).	 In	 this	 mechanism,	 the	 lysosomal	 recruitment	 of	 mTORC1	followed	 by	 its	 activation	 has	 been	 shown	 to	 be	 very	 specific	 and	 accurately	controlled	by	distinct	amino-	acid	residues.		Stimulation	 of	 mTORC1	 pathway	 results	 in	 activation	 of	 cell	 growth	 as	 well	 as	numerous	of	anabolic	processes	like	protein	and	lipid	synthesis.	Its	inhibition	has	the	opposite	action,	resulting	in	down-regulation	of	catabolic	pathways	as	well	as	induction	 of	 autophagic	 process	 (reviewed	 in	 (Laplante	 and	 Sabatini,	 2009)).	Deregulations	of	mTOR	pathway	can	be	found	in	several	pathological	conditions.	For	 example,	 mTOR	 hyper-activation	 is	 a	 common	 feature	 of	 numerous	 human	cancers	and	neurological	diseases	(e.g.	epilepsy,	autism)	whereas	decreased	mTOR	activity	is	linked	to	diseases	such	as	muscular	atrophy.	However,	the	reasons	why	changes	in	mTOR	activity	have	severe	consequences	remain	to	be	elucidated.			
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Figure2:	The	mammalian	target	of	rapamycin	(mTOR)	signaling	pathway	mTOR	complex	1	(mTORC1)	and	mTOR	complex	2	(mTORC2)	are	both	controlled	by	growth	factors.	Growth	factors	inhibits	the	tuberous	sclerosis	complex	(TSC1/2)	leading	to	mTORC1	activation.	TSC	acts	as	a	GTPase-activating	protein	(GAP)	for	the	small	GTPase	RAS	homologue	enriched	 in	 the	 brain	 (RHEB),	 when	 activated	 leads	 to	 mTORC1	 activation.	 AMP-activated	protein	kinase	(AMPK)	is	activated	in	response	to	a	low	energy	status	and	phosphorylates	the	regulatory-associated	protein	of	mTOR	(RAPTOR).	mTORC1	is	also	regulated	by	amino-	acids	and	 energy	 status	 (detailed	 on	 Fig.	 3).	 mTORC2	 activation	 by	 growth	 factors	 is	 controlled	through	the	classical	phosphatidylinositide	3-kinase	(PI3K)-AKT	pathway.	Collectively	multiple	stimuli	modulate	mTORC1	and	mTORC2	activity	in	order	to	maintaining	the	balance	between	anabolic	and	catabolic	reactions.				The	 regulation	 of	 mTOR	 pathway	 is	 extremely	 complex,	 far	 from	 being	 fully	understood.	 A	 well	 characterized	 upstream	 mode	 of	 regulation	 of	 mTORC1	 is	mediated	 via	 the	 tuberous	 sclerosis	 complex	 (Tsc)	 composed	 of	 two	 tumor	suppressor	genes	TSC1	and	TSC2	(TSC1/2).	The	Tsc	complex	is	a	GTPase	activating	protein	(GAP)	acting	towards	the	small	GTPase	Ras	homologue	enriched	in	brain	(Rheb).	Upon	environmental	or	cellular	stresses,	Tsc2	is	recruited	to	the	lysosome	and	 consequently	 inhibits	 Rheb’s	 function,	 leading	 to	 a	 negative	 regulation	 of	mTORC1	activity.	Tsc2	lysosomal	recruitment	is	a	general	mechanism	in	response	
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to	stress	and	results	in	mTORC1	down-regulation,	defining	Tsc2	as	a	physiological	suppressor	of	mTORC1	(Demetriades	et	al.,	1AD).		In	 ESCs,	 mTORC1	 activity	 is	 relatively	 low	 and	 gets	 rapidly	 upregulated	 upon	differentiation	(Sampath	et	al.,	2008).	In	a	large-scale	loss	of	function	genetic	screen	aiming	to	identify	genes	essential	for	exit	of	pluripotency,	TSC1/2	were	identified	as	genes	required	for	the	maintenance	of	self-renewal	ability	of	murine	ESCs	in	the	presence	 of	 differentiation’s	 stimuli.	 It	 was	 therefore	 surprising	 to	 identify	 an	mTORC1	 activator	 as	 an	 inhibitor	 of	 ESCs	 differentiation.	 However,	 the	differentiation	 defect	 downstream	 of	 TSC2	 LOF	 was	 reverted	 by	 rapamycin	treatment,	a	potent	mTORC1	inhibitor	(Betschinger	et	al.,	2013).	In	line	with	mTORC1	playing	an	important	role	during	embryonic	development,	a	recent	 study	 has	 shown	 that	 chemical	 inhibition	 of	 mTOR	 induces	 diapause,	 a	developmental	 arrest	 of	 the	 blastocyst	 corresponding	 to	 embryonic	 dormancy	(Bulut-Karslioglu	et	al.,	2016).				 2.3	The	lysosome	is	required	for	normal	developmental	progression		 	
2.3.1	The	lysosome			Lysosomes	are	organelles	localized	at	the	crossroad	between	anabolic	and	catabolic	reactions.	 They	 originate	 from	 early	 endosome	 and	 go	 through	 a	 series	 of	maturation	 processes.	 The	 lysosome	 has	 a	 double	 function	 in	 generating	fundamental	units	for	anabolic	reactions	as	well	as	in	removing	old	organelles	from	the	cell.	The	acidic	lysosomal	lumen	contains	several	enzymes	(e.g.	hydrolases)	that	allow	the	degradation	of	most	of	the	substrates	(Mindell,	2012).	At	its	surface,	the	proton	pump	V-ATPase	safeguards	the	maintenance	of	the	low	pH	of	the	lysosomal	lumen	and	impairment	of	lysosomal	acidification	leads	to	lysosomal	diseases	like	lysosomal	storage	disorders	(LSDs).	LSDs	cover	a	large	scope	of	syndromes	like	the	well-known	“Pompe	disease”,	a	neuromuscular	disorder	causing	muscle	weakness	or	also	the	Wolman’s	disease	with	lipid	accumulation	leading	to	obesity	(Du	et	al.,	1998).	 The	 lysosome	 can	 adapt	 to	 changes	 occurring	 in	 its	 environment	 and	lysosomal	functions	can	be	regulated	at	the	transcriptional	level	as	well	at	the	post-
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translational	level	((Sardiello	et	al.,	2009);	(Settembre	et	al.,	2012)	).	In	an	effort	to	understand	how	lysosomal	 turnover	 is	regulated,	a	system	biology	approach	has	identified	 the	 so	 called	 coordinated	 lysosomal	 enhancement	 and	 regulation	(CLEAR)	 transcriptional	 network,	 a	 nuclear	 response	 element	 that	 regulates	lysosomal	function	(Sardiello	et	al.,	2009).	This	approach	has	revealed	that	most	of	the	 identified	 lysosomal	genes	 contain	an	E-box,	 the	 target	 site	 for	 transcription	factors	having	in	their	structure	a	basic	helix-loop-helix	(bHLH).	The	transcription	factor	Tfe3	is	one	of	those	and	has	been	shown	to	maintain	a	pluripotent	state	in	ESCs	(Betschinger	et	al.,	2013).	Lysosome	are	key	players	in	autophagy,	a	conserved	pathway	 by	 which	 old	 organelles	 and	 other	 macro	 molecules	 are	 recycled.	Autophagy	 was	 shown	 to	 have	 an	 important	 role	 in	 development	 and	 loss	 of	function	of	beclin1,	an	important	regulator	of	autophagy	leads	to	early	embryonic	lethality	around	the	gastrulation	stage	(Yue	et	al.,	2003).	Additionally,	a	role	in	the	regulation	of	pluripotency	associated	proteins	has	also	been	described	 in	human	ESC	(Cho	et	al.,	2014).	Therefore,	the	lysosome	is	an	essential	organelle	acting	in	concert	 with	 extracellular	 and	 intracellular	 cues	 to	 control	 cellular	 energy	 and	differentiation.				
2.3.2	The	amino-acid	sensing	machinery		The	 recent	 finding	 of	 the	 amino-acid	 sensing	 machinery	 revealed	 a	 conserved	mechanism	from	yeast	to	Human	(Péli-Gulli	et	al.,	2015);	(Sancak	et	al.,	2008)	.	It	acts	in	sensing	nutrient	availability	required	to	execute	normal	cellular	processes.	Although	 the	 complex	 regulation	 of	 this	 pathway	 is	 not	 yet	 fully	 elucidated,	 the	amino-acid	 sensing	machinery	 acts	 in	 fine	 in	 regulating	 the	 activity	 of	mTORC1	kinase	 through	 its	 recruitment	 at	 the	 lysosome	 surface	 through	 the	 ragulator	complex	in	response	to	amino-acids	stimulation.		The	ragulator	is	a	pentameric	protein	complex	constituted	of	five	Late	Endosomal	Adaptor,	MAPK	and	mTOR	activator	(Lamtor)	proteins	localized	at	the	lysosomal	surface.	 It	 recruits	 and	 activates	 the	 small	 Rag	 GTPases	 by	 controlling	 their	nucleotide	loading	state	(Sancak	et	al.,	2010).	Lamtor1	acts	a	scaffold	for	the	entire	complex	 and	 secures	 its	 positioning	 to	 the	 lysosome.	 Lamtor1	 lysosomal	localization	is	secured	via	post-translational	modifications	(e.g.	 lipidation)	within	
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its	N-terminus	 (Nada	et	 al.,	 2014).	 In	 line	with	 its	well	 characterized	 function	 in	amino-	 acid-sensing,	 Lamtor1	 and	 Lamtor2	 deficient	 embryos	 die	 at	 around	embryonic	day	7-8,	demonstrating	an	important	role	of	these	proteins	for	normal	development	((Nada	et	al.,	2009);	(Teis	et	al.,	2006)).	Furthermore,	Lamtor3	was	identified	 in	 a	 genetic	 screen	 aiming	 to	 identify	 genes	 essential	 for	 ESCs	differentiation	 suggesting	 an	 important	 function	 so	 far	 unknown	 in	 ESC	 biology	(Westerman	et	al.,	2011).		Lamtor4	and	Lamtor5	were	identified	only	later	when	the	ragulator	was	shown	to	act	as	a	Guanine	Exchange	Factor	(GEF)	for	the	small	Rag	GTPases	RagA/B		(Bar-Peled	et	al.,	2012).	The	main	function	of	the	ragulator	takes	place	in	the	transduction	of	intra	lysosomal	amino-acid	concentrations	through	the	heterodimeric	complex	of	small	Rag	GTPases	consisting	of	the	redundantly	acting	Rag	GTPases	RagA	or	B	and	RagC	or	D.	In	the	absence	of	amino-acids	or	when	concentrations	decrease,	the	Rag	 GTPases	 heterodimer	 is	 in	 an	 inactive	 conformation	 as	 RagA/B-GDP	 and	RagC/D-GTP	(Shen	et	al.,	2017).	Increased	lysosomal	amino-acid	concentrations	are	sensed	by	the	ragulator	and	transduced	onto	the	inactive	RagA/B	GTPase	through	the	 GEF	 activity	 of	 the	 ragulator,	 via	 the	 lysosomal	 V-ATPase	 (Bar-Peled	 et	 al.,	2012).	 In	 contrast,	 the	 RagC/D	GTPases	 are	 activated	 by	 the	 cytoplasmic	 tumor	suppressor	 Folliculin	 (Flcn)	 (Tsun	 et	 al.,	 2013),	 but	 how	Flcn	 is	 activated	 in	 the	amino-acid	sensing	machinery	remains	poorly	understood.	In	fine,	the	amino-acid	mechanism	leads	to	the	lysosomal	recruitment	and	activation	of	mTORC1	(Sancak	et	al.,	2010).		Since	its	discovery,	the	knowledge	around	the	ragulator	continuously	increases.	It	is	now	known	that	the	Rag	GTPases	are	regulated	by	the	Gap	activity	towards	Rag	(Gator)	proteins	and	Gator1	itself	is	recruited	to	the	lysosome	through	the	protein	complex	 Kicstor	 composed	 of	 four	 proteins:	 KPTN,	 ITFG2,	 C12orf66	 and	 SZT2	(Wolfson	et	al.,	2017).		The	amino-	acid	sensing	mechanism	is	regulated	at	different	levels	and	early	studies	already	suggested	a	link	between	this	pathway	and	the	regulation	of	the	pluripotent	state	of	ESCs	(Westerman	et	al.,	2011).				
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Figure3:	mTORC1	complex	is	positively	and	negatively	regulated		The	 amino-acid	 sensing	 machinery	 (left	 part)	 senses	 amino-acid	 within	 the	 lysosomal	compartment.	 In	 the	 presence	 of	 amino-acids,	 the	 lysosomal	 lumen	 signals	 to	 the	 ragulator	through	the	v-ATPase.	Once	activated,	the	ragulator	activates	RagA/B	via	its	guanine	exchange	factor	(GEF)	function.	In	fine,	it	leads	to	the	lysosomal	recruitment	of	mTORC1	followed	by	its	activation	via	Rheb.	This	pathway	has	different	levels	of	regulation	ensured	by	positive	(yellow)	and	negative	(blue)	regulators.	Figure	taken	from	(Saxton	and	Sabatini,	2017) 			
2.3.3	 Folliculin	 is	 required	 for	 developmental	 progression	 and	 metabolic	
functions		Developmental	progression	is	often	associated	with	metabolic	pathways	rewiring.	Indeed,	tremendous	research	work	was	conducted	in	order	to	identify	intracellular	molecular	 sensors	 that	 convey	 the	 nutritional	 availability	 information	 from	 the	extracellular	toward	the	intracellular	environment.	On	the	above	described	amino-acid	sensing	mechanism	is	mentioned	Folliculin	(Flcn).	Flcn	is	a	tumor	suppressor	gene,	 evolutionarily	 conserved	 and	 germ	 line	 heterozygous	mutations	 cause	 the	autosomal	 disorder	 called	 the	Birt-Hogg-Dubé	 (BHD)	 syndrome,	 associated	with	renal	cell	carcinoma	(Linehan	et	al.,	2010).	Additionally,	inactivation	of	Flcn	induces	
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transcriptional	 activity	 of	 the	 transcription	 factor	 Tfe3	 by	 increasing	 its	 nuclear	localization	(Hong	et	al.,	2010).		In	murine,	 Flcn	LOF	embryos	are	not	 viable	 and	die	 around	E6.5	 (Hasumi	et	 al.,	2009).	Nevertheless,	conditional	knock	out	mice	carrying	a	deletion	in	Flcn	locus	in	muscle	 were	 generated	 to	 study	 the	 potential	 role	 of	 Flcn	 in	 metabolism	 and	revealed	 an	 increased	 mitochondrial	 biogenesis	 mediated	 via	 the	 transcription	factor	PGC-1alpha	(Hasumi	et	al.,	2012).	Flcn	LOF	associated	tumors	were	reported	to	 display	 increased	 mTOR	 activity	 (Baba	 et	 al.,	 2008).	 Interestingly,	 two	independent	in	vitro	studies	using	two	different	cell	lines	have	shown	that	Flcn	LOF	results	in	down-regulation	of	mTORC1	activity	in	one	case	whereas	mTORC1	was	up-regulated	in	the	other	cell	line	((Baba	et	al.,	2006);	(Hudon	et	al.,	2010)).	These	paradoxical	observations	suggest	an	intricate	mechanism	of	regulation	dictated	by	Flcn.	 On	 one	 side,	 Flcn	 activates	 mTORC1	 in	 an	 amino-acid	 dependent	 manner	whereas	 Flcn	 LOF	 can	 increase	mTORC1	 activity.	 To	 unravel	 the	mechanism	 in	which	 Flcn	 is	 acting,	 Flcn	 LOF	 ESCs	 have	 been	 generated	 in	 a	 study	 that	 has	identified	 a	 role	 for	 Flcn	 in	 conferring	 apoptotic	 resistance	 due	 to	 loss	 of	 Bim	expression	 (Cash	 et	 al.,	 2011).	 Molecularly,	 Flcn	 forms	 a	 complex	 with	 two	cytoplasmic	Flcn-interacting	partner	partners	Fnip1/2.	It	has	been	suggested	that	FLCN	 and	 FNIP1	 are	 involved	 in	 a	metabolic	 pathway	 involving	 energy	 sensing	where	 Fnip1	 has	 been	 shown	 to	 be	 targeted	 by	 AMPK	 through	 an	 unknown	mechanism	(Baba	et	al.,	2006).		However,	despite	its	implication	in	several	diseases	and	numerous	pathways,	the	role	of	Flcn	in	development	remains	unclear.	Flcn	has	been	identified	in	a	genetic	screen	using	small	interference	RNA	(siRNA)	aiming	to	identify	genes	required	for	exit	 from	 pluripotency	 in	 ESCs.	 As	 shown	 in	 other	 cell	 type,	 Flcn	 and	 its	 two	interacting	 partners	 Fnip1/2,	 regulate	 the	 subcellular	 localization	 of	 the	 bHLH	transcription	 factor	 Tfe3	 and	 Flcn	 loss	 of	 function	 ESCs	 are	 consequentially	impaired	for	differentiation	(Betschinger	et	al.,	2013).	The	recent	finding	of	Flcn	acting	as	a	GAP	towards	the	small	GTPase	RagC	in	vitro	has	allowed	to	replace	Flcn	 in	a	metabolic	pathway	taking	place	at	 the	 lysosome	((Petit	 et	 al.,	 2013);	 (Tsun	 et	 al.,	 2013)),	 but	whether	 Flcn	 acts	 similarly	 in	 ESC	differentiation	 is	 unclear.	 Another	 study	 has	 shown	 that,	 in	 normal	 culture	
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conditions,	 a	 portion	of	 Flcn	 resides	 on	 the	 lysosome	and	 that	 Flcn	mediates	 an	alternative	mTORC1	 pathway	 to	 regulates	 browning	 of	 adipose	 tissue	 involving	Tfe3	 (Wada	et	al.,	2016).	Taken	 together,	 this	 suggests	 that	Flcn’s	main	 function	might	take	place	around	this	organelle.	How	Flcn	acts	during	early	development	upstream	of	Tfe3	and	why	this	pathway	appears	to	be	so	crucial	for	ESC	differentiation	remains	an	outstanding	question.		
2.3.4	The	MiT	family	of	transcription	factor			The	MiTF	transcription	factors	family	is	composed	of	four	evolutionarily	conserved	homologous	proteins	encoded	by	four	distinct	genes	called	MITF,	TFEB,	TFE3	and	TFEC,	all	sharing	structural	homologies.	Their	structure	is	formed	by	a	double	helix	leucine	 zipper	 motif,	 a	 transactivating	 domain	 and	 a	 DNA	 binding	 motif	 that	recognizes	 E-box	 in	 the	 genome.	 In	 order	 to	 activate	 transcription,	 MiT/TFE	transcription	factors	must	dimerize	with	another	member	of	the	MiT/TFE	family	that	included	homodimer	formation.	Although	Tfe3	and	Tfeb	have	been	the	most	extensively	described,	the	two	other	family	members	remain	functional.	TfeC	has	a	role	 in	 monocyte	 (Rehli	 et	 al.,	 1999)	 whereas	 Tfeb	 plays	 a	 role	 in	 osteoclast	differentiation	(Yoneshima	et	al.,	2015).	MiTF	expression	occurs	essentially	during	embryonic	 development	 and	 has	 a	 regulatory	 function	 for	 melanocytes	differentiation	(Levy	et	al.,	2006).	Mutations	in	the	MITF	locus	are	associated	with	a	 rare	 genetic	 disorder	 called	 the	 Waardenburg	 syndrome	 characterized	 by	permanent	 hearing	 loss	 and	 heterochromia	 of	 the	 irises	 (Baral	 et	 al.,	 2012);	(Watanabe	et	al.,	1998).		Although	Tfeb	LOF	in	embryo	is	lethal	at	an	early	developmental,	Tfe3	KO	mice	are	viable	 and	have	been	 reported	 to	 be	healthy	without	 any	observable	phenotype	(Steingrimsson	et	al.,	2002).	This	already	suggests	distinct	functions	for	Tfeb	and	Tfe3	during	development.	Moreover,	a	recent	study	involving	the	tumor	suppressor	gene	Flcn	have	shown	that	Tfe3	KO	mice	display	bigger	adipose	 tissues	and	will	eventually	become	obese	at	a	later	stage	(Wada	et	al.,	2016).	At	 the	 cellular	 level,	 Tfe3	 and	 Tfeb	 are	 essentially	 cytoplasmic	 under	 normal	conditions	while	they	localize	exclusively	in	the	nucleus	in	response	to	stress	(e.g.	
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nutrient	 starvation).	 Supporting	 this	 finding,	 Tfeb	 overexpression	 increases	lysosomal	content	and	catabolic	activity.	Tfeb	is	a	master	transcriptional	regulator	of	lysosomal	biogenesis	and	autophagy;	in	the	nucleus,	Tfeb	was	shown	to	bind	the	Coordinated	Lysosomal	Expression	and	Regulation	(CLEAR)	element	response	sites	involved	in	lysosomal	biogenesis	(Sardiello	et	al.,	2009).	Importantly,	all	the	MiTF	transcription	factors	can	bind	CLEAR	element	response.				
 
 
	
Figure	4:	Tfe3	subcellular	localization	at	early	developmental	stages	in	vivo	At	embryonic	day	(E)	3.5,	Tfe3	is	essentially	found	in	the	nucleus.	One	day	later,	within	ESCs	of	the	ICM	it	becomes	present	 in	both	nuclear	and	cytoplasm	whereas	 in	the	post-implantation	epiblast,	it	is	found	only	in	the	cytoplasm.					Although	 the	 MiTF	 transcription	 factors	 display	 strong	 similarities,	 they	nevertheless	display	distinct	roles	in	different	biological	processes.	Together,	Tfe3	and	Tfeb	are	at	the	crossroad	with	the	mTORC1	signaling	pathway.	Upon	lysosomal	recruitment,	mTORC1	phosphorylates	the	cytoplasmic	protein	14-3-3	(Martina	and	Puertollano,	2013).	When	phosphorylated,	14-3-3	 can	bind	Tfeb	and	Tfe3	 in	 the	cytoplasm.	 Tfe3	 and	 Tfeb	 have	 also	 been	 described	 as	 mTORC1	 targets	 and	phosphorylation	by	mTORC1	leads	to	their	cytoplasmic	inactivation	(Martina	et	al.,	2014).	Interestingly,	hyperactivation	of	mTORC1	in	response	to	Tsc2	LOF	in	ESCs	leads	 to	 a	 differentiation	 block	 accompanied	 by	 nuclear	 localization	 of	 Tfe3	(Betschinger	et	al.,	2013)	.	Another	mode	of	regulation	of	Tfeb	is	mediated	calcium	release	 from	 the	 lysosome	 that	 activates	 calcineurin,	a	calcium	and	calmodulin	dependent	serine/threonine	protein	phosphatase,	which	binds	and	dephosphorylates	Tfeb,	thus	promoting	its	nuclear	translocation	(Medina	
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et	 al.,	 2015).	 In	 addition,	 Tfeb	 also	 contains	 a	 nuclear	 localization	 signal	 in	 its	structure	 that	 is	 covered	 by	 phosphorylation	 sites	 important	 for	 its	 nuclear	translocation.	In	wildtype	ESCs,	Tfe3	is	ubiquitously	detected	in	both	nuclear	and	cytoplasmic	compartment,	in	vitro	as	well	as	in	in	vivo	conditions	(figure4).	Upon	differentiation,	Tfe3	is	excluded	from	the	nucleus	and	consistently,	ectopic	nuclear	expression	of	Tfe3	 inhibits	ESC	differentiation	 in	vitro	(Betschinger	et	al.,	2013).	Tfe3	 is	 ubiquitously	 expressed	 and	 is	 also	 the	 target	 of	 numerous	 chromosomal	translocations	 that	 have	 been	 implicated	 in	 diseases	 (e.g.	 renal	 cell	 carcinoma)	(reviewed	in	(Kauffman	et	al.,	2014)).	Tfe3	gene	fusion	mechanism	remains	poorly	understood	but	all	Tfe3	fusion	proteins	lead	to	its	over-expression	and,	similar	to	Flcn	LOF,	cause	the	BHD	syndrome.					
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3	Scope	of	this	thesis			Embryonic	stem	cells	 (ESCs)	have	 the	unique	potential	 to	give	rise	 to	any	of	 the	three	 germ	 layers	 when	 exposed	 to	 differentiation	 stimuli.	 Maintenance	 of	 the	ground	state	of	pluripotency	in	vitro	is	well	understood	but	the	control	of	its	loss	is	less	so.	Previously,	a	large-scale	loss	of	function	genetic	screen	has	identified	a	set	of	 genes	 required	 for	 the	 exit	 from	pluripotency,	 amongst	others	 identifying	 the	tumor	 suppressor	 gene	 Folliculin	 (Flcn)	 (Betschinger	 et	 al.,	 2013).	 Flcn	 acts	upstream	 of	 the	 bHLH	 transcription	 factor	 Tfe3	 by	 controlling	 its	 subcellular	distribution,	 thereby	 constituting	 a	 novel	 pathway	 in	 the	 control	 of	 ESC	differentiation.	However,	how	Flcn	mechanistically	regulates	this	pathway	remains	to	be	determined.		In	the	first	part	of	the	work	presented	here,	we	aimed	to	understand	the	molecular	framework	in	which	Flcn	and	Tfe3	act	together.	We	used	a	selective	genetic	loss	of	function	screen	to	identify	genes	with	a	Flcn-like	phenotype.	To	further	understand	how	Tfe3	subcellular	localization	is	regulated,	we	investigated	Tfe3	specific	binding	partners	as	well	as	potential	post-translational	modifications.	In	somatic	cells,	Flcn	acts	in	a	metabolic	pathway	sensing	nutrient	availability	which	in	fine	regulates	the	activity	 of	 mTORC1	 kinase.	 We	 therefore	 asked	 if	 nutrients	 act	 instructively	upstream	 of	 Flcn	 in	 ESCs.	 Although	 alteration	 of	 mTORC1	 activity	 does	 neither	perturb	ESCs	self-renewal	ability	nor	differentiation,	additional	analysis	revealed	that	hyperactive	mTORC1	dominantly	interferes	with	the	Flcn-Tfe3	pathway.			To	gain	further	insight	into	how	this	differentiation	pathway	contributes	to	human	development	 and	 disease,	 we	 identified	 uncharacterized	 Tfe3	 patient	mutations	associated	with	a	developmental	disorder.							
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4	Results	
	4.1	 Lysosomal	 signaling	 is	 required	 for	 embryonic	 stem	 cell	differentiation	and	human	development	
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Abstract 
Self-renewal and differentiation of pluripotent murine embryonic stem cells (ESCs) is 
balanced by extrinsic signalling pathways 1. It is less clear if cellular metabolism instructs 
developmental progression. In an unbiased genome-wide CRISPR/Cas9 screen, we 
identify lysosomal signalling components as critical drivers of ESC differentiation. 
Functional analysis revealed that lysosome activity, the Ragulator protein complex and 
the tumor-suppressor protein Folliculin regulate the Rag GTPases C and D, which in turn 
bind and sequester the bHLH transcription factor Tfe3 in the cytoplasm. In contrast, 
ectopic nuclear Tfe3 induces transcriptional programs related to embryonic diapause and 
antagonizes transcriptional remodelling during differentiation. Importantly, we also 
identify point mutations in a Tfe3 domain required for cytoplasmic inactivation as causal 
for a novel human developmental disorder. This reveals a conserved and biomedical 
relevant role of lysosomal signalling in licensing embryonic cell fate transitions. 
 
Results 
Chemical inhibition of glycogen synthetase kinase 3 and fibroblast growth factor (FGF) 
signalling (2 inhibitors, 2i) confers an undifferentiated and self-renewing ESC state. 
Release from 2i induces exit from self-renewal and, eventually, terminal differentiation 
1. In order to identify molecular mechanisms essential for this process, we screened for 
genes whose deletion would block differentiation. Towards this goal we infected Cas9-
expressing RGd2 ESCs with a genome-wide lentiviral guide RNA (gRNA) library 2 and 
continuously passaged these cells in the absence of 2i. To enrich for differentiation 
resistant mutant cells, we concomitantly selected for expression of the Rex1 (Zfp42) 
reporter in RGd2 cells, which marks self-renewing ESCs 3 (Fig. 1a). This screen was 
performed independently in two female ESC clones and identified 19 high-confidence 
target genes (Fig. 1b, Extended Data Fig. 1a, Supplementary Table 1). We validated the 
differentiation-resistance phenotype for 15 of those in a male RGd2 ESC line that was 
transiently transfected with Cas9 and individual gRNAs (Extended Data Fig. 1a). For 
phenotypic stratification, we also monitored the subcellular localization of the 
transcription factor Tfe3. Its cytoplasmic redistribution is associated with developmental 
progression of mouse blastocysts and murine and human pluripotent stem cells, while 
ectopic nuclear Tfe3 impairs ESC differentiation 3-7. In contrast to cytoplasmic 
accumulation in differentiated wildtype cells (Extended Data Fig. 1h) and seven of the 
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differentiation-resistant mutants, Tfe3 was nuclear in the absence of Folliculin (Flcn), 
Lamtor1, 2, 4 and 5, and Tuberosclerosis complex (Tsc) 1 and 2 (Fig. 1c, Extended Fig. 
1b). Surprisingly, two gRNAs that specifically target exon 4 of Tfe3 generated Tfe3 
alleles with ectopic nuclear localization (Fig. 1c). Regulation of exit from pluripotency 
via subcellular Tfe3 localization by Flcn, Tsc1 and 2 has been described before, yet the 
regulatory framework they act in ESCs remained undefined 4. Lamtor3 was suggested to 
direct the outcome of FGF signalling in ESCs 8, but based on phenotypic similarity we 
hypothesized that Lamtor proteins and Flcn may function together in exit from self-
renewal. We first confirmed the role of Lamtor1, 2, and 3 in an independent assay. 
Knockdown in Oct4GIP ESCs by siRNA transfection induced nuclear enrichment of 
Tfe3 and impaired differentiation, similarly to absence of Flcn and the redundantly acting 
Folliculin-interacting partners Fnip1/2 (Extended Data Fig. 1c-e). To test for Tfe3-
dependency, we co-depleted Tfe/Mitf family members expressed in ESCs (data not 
shown). Removal of Tfe3, but not Tfeb or Mitf, reverted differentiation defects caused 
by knockdown of Flcn and Lamtor1 and 2, but not Tcf7l1 (Fig. 1d), demonstrating a 
specific requirement for Tfe3 downstream of these genes. For further analysis, we 
generated isogenic Flcn and Lamtor1 (LT1) knockout (KO) ESC clones (Extended Data 
Fig. 1f). These maintained nuclear Tfe3 localization (Extended Fig. 1h) and failed to exit 
self-renewal under two different differentiation regimes; removal of 2i and the strongly 
inductive epiblast like cell (EpiLC) differentiation 9 (Fig. 1e). Both phenotypes were 
rescued by Flcn and Lamtor1 transgene expression in the respective mutants (Fig. 3b-d). 
Long-term culture of Flcn and Lamtor1 KO ESCs in the absence of 2i gave rise to cell 
populations retaining self-renewal, which is similar to induction of ectopic nuclear Tfe3 
in 4-Hydroxy-Tamoxifen (Tam)-treated Tfe3-ERT2 expressing cells (Extended Data Fig. 
1i) 4. In summary, loss of Lamtor proteins, similarly to loss of Flcn, induces an ESC 
differentiation block that is dependent on nuclear Tfe3. 
To gain insight into Flcn and Lamtor1 function, we compared the transcriptomes of two 
independent Flcn and Lamtor1 KO ESC lines and their respective controls 
(Supplementary Table 1). Importantly, transcriptional deregulation in both KO ESCs was 
strongly correlated (Pearson correlation coefficient R=0.70) (Extended Data Fig. 2a), 
suggesting that both genes act in the same pathway. To further explore the relation with 
Tfe3 activity, we profiled Tfe3-ERT2 expressing ESCs after 3 hours (h) and 34h of Tam 
induction. The short treatment resulted almost exclusively in transcriptional 
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upregulation, indicating that Tfe3 acts as an activator (Supplementary Table 1). 
Comparison with prolonged nuclear Tfe3 induction and Flcn and Lamtor1 KO ESCs 
identified groups of early, late and indirect target genes, and revealed adaption to 
continuous Tfe3 activation in established KO cell lines (Fig. 2a, Extended Data Fig. 2b-
d). To test if transcriptional changes recapitulate a defined stage of embryogenesis, we 
compared them with published datasets of blastocyst development 10. In particular the 
34h Tfe3 activation in Tfe3-ERT2 ESCs showed a correlation to induction of diapause, 
an embryonic state of suspended development (Extended Data Fig. 2c). While this 
correlation is not strong (R=0.22), it is comparable to reported diapause mimicking ESC 
regimes using chemical inhibitors 11,12. Direct comparison to these treatments revealed 
higher similarities to Myc-inhibition 11 than inhibition of mTOR 12 (Extended Data Fig. 
2c,e), suggesting regulation of a specific subset of shared target genes. 
Transcriptional similarity between diapaused embryos and ESCs with ectopic nuclear 
Tfe3 may reflect a common causal contribution to the inhibition of developmental 
progression in vivo and in vitro. To directly explore the role of Tfe3 in differentiation, 
we sequenced Flcn KO and nuclear Tfe3-induced Tfe3-ERT2 cells 34h after 2i 
withdrawal, and compared transcriptional changes to blastocyst development 10 and 
EpiLC differentiation 13 (Extended Data Fig. 2f, Supplementary Table 1). Principal 
component analysis separated ESCs and the E4.5 epiblast from 34h differentiated cells, 
EpiLCs and the E5.5 epiblast along principal component 2 (PC2) (Fig. 2b). In contrast, 
34h differentiated Flcn KO and Tfe3-induced cells and their long term differentiated 
progeny, including Lamtor1 KO cells, clustered close to wildtype ESCs, suggesting 
transcriptome-wide impairment of peri-implantation programs. For further 
characterization, we performed k-means clustering of transcripts changing 34h after 2i 
removal in wildtype cells or being specifically deregulated during differentiation of Flcn 
KO and Tam-treated Tfe3-ERT2 cells (Fig. 2c, Extended Data Fig. 2b). Dynamics of 
genes in clusters 9 and 10 were unaffected by perturbations, while cluster 11 contained 
transiently induced Tfe3-targets. In contrast, clusters 12 and 13 made up more than half 
of the transcripts that were regulated during wildtype differentiation, but dynamics were 
significantly dampened upon genetic perturbations (data not shown). Gene ontology 
(GO) analysis revealed enrichment of developmental and lysosomal function in cluster 
11 and 12, respectively. Intriguingly, transcriptional deregulation of these clusters was 
already detectable in mutant ESCs (Fig. 2c). However, attenuation during differentiation 
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is likely not a consequence of preceding ESC perturbations since Tam was added to Tfe3-
ERT2 cells during differentiation only. Taken together, these findings suggest that 
ectopic nuclear Tfe3 mitigates large parts of the transcriptional routines underlying exit 
from ESC self-renewal, and that this repression is independent of the cell state. 
Identification of Tfe3-regulated differentiation-associated lysosomal target genes 
furthermore indicates coordination of developmental and metabolic programs by the 
Flcn-Lamtor-Tfe3 axis. 
Lamtor proteins form a lysosomal membrane-associated protein complex called 
Ragulator 14, which recruits a Rag GTPase heterodimer consisting of the redundantly 
acting RagA or RagB and RagC or RagD 15. Combinatorial depletion of RagA/B or 
RagC/D in ESCs caused nuclear Tfe3 accumulation and Tfe3-dependent differentiation 
impairment (Fig. 1d, Extended Data Fig. 1c-e), which indicates a crucial role of Rag 
GTPases in exit from self-renewal. Flcn acts as a GTPase activating protein (GAP) on 
RagC and RagD in vitro 16-18, and overexpression of RagC and RagD mutants 
preferentially binding GDP (RagC/D-GDP) 16 reverted nuclear Tfe3 localization and 
differentiation impairment in Flcn KO cells (Extended Data Fig. 3a,b). In contrast, 
GTPase-inactive mutants of RagC and RagD (RagC/D-GTP) 16 or any nucleotide-loading 
RagB-mutant failed to do so, suggesting that Flcn controls the nucleotide state of RagC/D 
but not RagA/B to drive ESC differentiation. 
In ESCs, RagC, Lamtor1 and a subfraction of endogeneously tagged Flcn colocalize with 
the lysosomal protein LAMP1 (Fig. 3a). Lysosomal RagC localization requires Lamtor1, 
2 and 3, but not Flcn (Extended Data Fig. 3c). To test the requirement for lysosomal 
localization we expressed RagB and RagC fused to the N-terminal lysosomal targeting 
sequence of Lamtor1 (LTS) 19 (Extended Data Fig. 3d). LTS-RagC but not LTS-RagB 
reverted nuclear Tfe3 localization and differentiation resistance in Lamtor1 KO ESCs 
(Fig. 3b,c). This indicates that lysosomal RagC/D but not RagA/B is sufficient in the 
absence of a functional Ragulator complex. Consistent with the notion that Flcn acts 
upstream of the RagC/D nucleotide state and independently of lysosomal recruitment, 
LTS-RagC failed to rescue Flcn KO phenotypes, while LTS-RagC-GDP did so (Fig. 
3b,d). Conversely, LTS-RagC-GTP dominantly induced nuclear Tfe3 localization and 
Tfe3-dependent differentiation impairment in wildtype cells (Extended Data Fig. 3e-g). 
Taken together these results suggest that the principal role of Ragulator in exit from ESC 
self-renewal is the lysosomal recruitment of RagC/D, which subsequently serve as a 
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substrate for Flcn GAP activity to drive cytoplasmic sequestration of Tfe3 and 
differentiation. 
To directly address the role of the lysosome in this process we applied lysosome 
perturbing drugs. Addition of the v-ATPase inhibitors BafilomycinA (BafA) and 
ConcanamycinA (ConA), the lysosomotropic compound Chloroquine, or Vacuolin-1, 
which impairs delivery and maturation of lysosomal enzymes 20, indeed impaired exit 
from self-renewal (Extended Data Fig. 3h,i). Since BafA, ConA and Chloroquine also 
triggered dose-dependent cell lethality (data not shown) we focussed our further efforts 
on Vacuolin-1. Treatment with Vacuolin-1 induced nuclear Tfe3 translocation (Extended 
Data Fig. 3j), while expression of LTS-RagC-GDP or knockout of Tfe3 (Extended Data 
Fig. 1f,g) rescued Vacuolin-1-elicited resistance to differentiation (Fig. 3e,f). Despite 
altered morphology in Vacuolin-1-treated cells, LAMP1-marked lysosomes still 
colocalized with RagC (Extended Data Fig. 3j), indicating an intact, but likely inactive 
Ragulator-Rag GTPase complex. This suggests that lysosomes not only provide a 
membranous interaction surface for assembling Rag GTPase signalling, but that 
lysosome function per se is required upstream of the RagC/D nucleotide state and Tfe3 
to drive exit from pluripotency. 
To explore how signalling at the lysosomal membrane regulates Tfe3, we determined the 
Tfe3 interactome in ESCs using label-free quantitative mass spectrometry (Fig. 3g,h, 
Supplementary Table 2). Tfe3 in RagC/D-GDP overexpressing ESCs specifically 
interacted with the Ragulator-Rag protein complex, with members of the lysosomal v-
ATPase, and with 14-3-3 protein-family members (Fig. 3h). Pulldown of Tfeb by the 
RagA/B-GTP - RagC/D-GDP heterodimer in human cell lines has been reported before 
21, but Tfe3 failed to interact with any RagB nucleotide loading mutant in ESCs (data not 
shown), demonstrating RagC/D specificity. Association of Tfe3 with Ragulator, Rag 
GTPases and v-ATPase proteins was undetectable in wildtype ESCs (Fig. 3g), suggesting 
transient and nucleotide-dependent binding that induces stable cytoplasmic 
sequestration, likely via further posttranslational modifications. To test the necessity of 
this interaction in the context of the endogenous Rag nucleotide cycle, we expressed in 
Tfe3 KO ESCs inducible Tfe3 alleles with mutations in residues homologous to the ones 
required for interaction of Tfeb with the active RagA/B-C/D heterodimer 21. In contrast 
to wildtype Tfe3, Tfe3(S111A, R112A) and Tfe3(Q118A, L119A) localized to the 
nucleus and impaired exit from self-renewal (Fig. 3i,j), indicating that association of Tfe3 
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with endogenous RagC/D-GDP is required for nuclear exclusion and ESC differentiation. 
14-3-3 proteins recognize phosphorylated Ser and Thr residues, and 14-3-3 binding and 
Ser phosphorylation have previously been implicated in controlling the subcellular 
localization of Tfe/Mitf family members 21,22. We therefore generated Tfe3 alleles with 
Ala mutations in respective Ser residues. This revealed that Tfe3(S245A) 23 and 
Tfe3(S320A) 24 were partially,  and Tfe3(S245,S320A) exclusively nuclear when 
compared to wildtype Tfe3 and Tfe3(10xA) 25 (Fig. 3i). Single and double Tfe3 mutants 
also impaired exit from self-renewal (Fig. 3j), suggesting that S245 and S320 
phosphorylation, downstream of RagC/D-GDP, is necessary for 14-3-3 protein-mediated 
cytoplasmic Tfe3 retention. This requirement for, at least, two posttranslational 
modifications is consistent with multiple additional levels of regulation.  
We therefore tested mechanisms described to modulate Tfe/Mitf transcription factors, 
including protein kinases C (PKCs) 26, Mcoln1-dependent regulation of the phosphatase 
Calcineurin 27, and the mechanistic target of Rapamycin (mTOR) complex 1 (mTORC1) 
24. Presence of the pan-PKC inhibitor Gö6983 caused nuclear Tfe3 enrichment and 
impaired differentiation (Extended Data Fig. 4a,b) 28, but these defects were insensitive 
to overexpression of LTS-RagC-GDP, demonstrating additional Rag GTPase-
independent mechanisms such as NFκB regulation 28. Knockdown of Mcoln1, the 
calcineurin catalytic subunit isoform beta (Ppp3cb), mTOR and the mTORC1 subunit 
Raptor, or treatment with the mTOR inhibitors AZD8055 and Rapamycin (Rapa) did not 
cause retention of self-renewal or revert resistance to differentiation in the absence of 
Lamtor1 (Extended Data Fig. 4c-e). Developmental progression of ESCs is therefore 
independent of Calcineurin or mTORC1 activation. The latter is surprising since 
mTORC1, via phosphorylation of S320, promotes cytoplasmic Tfe3 translocation upon 
release from amino acid starvation in somatic cell lines, and since Flcn, Ragulator and 
Rag GTPases are required for recruitment and activation of mTORC1 in this context 22. 
This suggests decoupling of lysosomal signalling and mTORC1 activity in ESCs. 
Consistently, phosphorylation of the mTORC1-targets S6 kinase (S6K) and 4EBP1 was 
not significantly altered upon knockout of Flcn and Lamtor1 (Extended Data Fig. 4f) or 
overexpression of LTS-RagC mutants (data not shown), and transcriptional deregulation 
in Flcn and Lamtor1 KO ESCs did not correlate with mTOR-inhibition 12 (Extended Data 
Fig. 2c). Furthermore, removal of essential amino acids induced nuclear Tfe3 
localization, but resistance to differentiation in these conditions was not reverted by LTS-
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RagC-GDP expression or in Tfe3 KO ESCs (Extended Data Fig. 4g,h). Taken together 
these observations suggest a RagC/D-dependent, but mTORC1 activation-independent 
mechanism driving ESC differentiation. We also did not identify any mTORC1-
activator, but, surprisingly, only the mTORC1-inhibitors Tsc1 and Tsc2 in our primary 
screen (Fig. 1b). Loss of Tsc2 by siRNA transfection or in KO ESCs impaired 
differentiation upstream of hyperactive mTORC1 (Extended Data Fig. 4d,e,i,j) 4, nuclear 
Tfe3 and RagC/D-nucleotide loading (Fig. 1d, Extended Data Fig. 4k-m). Tsc2-
dependent mTORC1 inhibition and Flcn-Ragulator-function therefore converge on 
RagC/D-GDP to promote exit from self-renewal. This is an unexpected observation and 
we therefore speculated that hyperactive mTORC1 and ectopic nuclear Tfe3 may exhibit 
similar phenotypes in other developmental systems. 
Tsc1/2 and Flcn loss of function mutations, hyperactive mTOR alleles and deletion of 
Tfe3 exons1-3 by translocation to distinct partner genes are frequently detected in renal 
cell carcinoma 29,30. The molecular consequences of these Tfe3 alterations are poorly 
understood 29, but our findings predict them to behave as nuclear gain of function alleles. 
We therefore conditionally expressed corresponding Tfe3 deletions in Tfe3 KO ESCs 
(Fig. 4a). Inclusion of exon3 (exon3-end) recapitulated cytoplasmic localization of 
wildtype Tfe3, while removal (exon4-end) induced nuclear translocation and impaired 
differentiation (Fig. 4b,c), suggesting that it is the absence of exon3 and not the presence 
of fusion partners that underlies oncogenic activity of chromosomal Tfe3 
rearrangements. Surprisingly, transcript sequencing of gain of function Tfe3 alleles 
recovered in our screen (Fig. 1b,c, Extended Data Fig. 1a) revealed small in-frame-
deletions frequently involving T180-P185 and skipping of exon4 rather than exon3 (data 
not shown). Nuclear localization of Tfe3Δexon4 protein and resistance to differentiation 
was validated in a Tfe3 exon4 skipping mutant ESC clone generated by an independent 
gRNA (Extended Data Fig. 1f, 5a,b) and in Tfe3 KO cells harbouring inducible 
Tfe3Δexon4 transgenes (Fig. 4a-c). Alterations in exon4 have, however, not been 
associated with disease as of now. 
Mosaic	mTOR	gain	of	function	alleles	also	cause	pigmentary	mosaicism	31,	but	mutations	
in	 Flcn	 or	 Tfe3	 have	 not	 been	 associated	 with	 this	 phenotype	 before.	 Pigmentary	
mosaicism	 and	 hypomelanosis	 of	 Ito	 (HI,	 MIM	 300337)	 are	 unspecific	 terms	
encompassing	 a	 heterogeneous	 group	 of	 disorders	 characterized	 by	 hypopigmented	
31	
whorls	and	streaks	along	Blaschko’s	lines	and	variable	extracutaneous	features	affecting	
the	 musculoskeletal	 and	 nervous	 systems	 32.	 In	 a	 program	 designed	 to	 identify	
underlying	genetic	causalities	in	a	cohort	of	patients	recruited	for	HI	using	whole-exome	
sequencing	 we	 identified	 four	 de	 novo	 germline	 (female	 patient	 1:	 Q119P,	 female	
patient	2:	Q201P,	female	patient	3:	T187M,	female	patient	5:	P186L)	and	one	de	novo	
mosaic	(male	patient	4:	T187R)	mutations	in	TFE3	(Fig.	4d,	Supplementary	Clinical	Data,	
Supplementary	Table	3).	Patient	phenotypes	included	hypopigmentation	on	Blaschko’s	
lines,	 severe	 intellectual	 disability	 (ID),	 coarse	 facial	 features,	 frontonasal	 dysplasia,	
obesity,	 epilepsy	 and	 growth	 retardation,	 suggesting	 a	 pleiotropic	 developmental	
disorder.	All	five	TFE3	variants	affect	conserved	amino	acids	(Fig.	S5c),	and	the	missense	
variants	 are	 in	 silico	 predicted	 as	 pathogenic	 (Supplementary	 Table	 3).	 The Q119P 
mutation resides in exon3 and affects an amino acid implicated in Rag interaction (Fig. 
3i, j)21, while the remaining four mutations (P186L, T187M, T187R, and Q201P) induce 
amino acid changes in exon4. Nuclear localization and resistance to differentiation were 
validated in Tfe3 KO ESCs expressing murine Tfe3 alleles (Q118P and P185L) (Fig. 
4e,f). Secondary structure analysis of Tfe3 using I-Tasser 33 predicts residues 110-215, 
encoded by exon3 and exon4, to form a domain of two stable α-helices  (Extended Data 
Fig. 5c). The Q->P mutations at positions 119 and 201 are likely disrupting helix 
formation. The two helices are connected by a short loop and an induced α-helix, and 
contain the highly-conserved residues P186 and T187 that may be crucial for Rag C/D 
interaction. These observations suggest that exon3 and exon4 form a Rag binding fold 
whose structural integrity is indispensable for cytoplasmic Tfe3 inactivation and, 
consequentially, ESC differentiation, human development and kidney tumor suppression. 
 
Here we show that lysosomal Rag GTPases drive ESC differentiation by inactivating 
Tfe3 through cytoplasmic redistribution. Interference with this regulation through 
mutations that	 produce	 inactivation-resistant, ectopic	 nuclear,	 Tfe3	 proteins	 are 
associated with pleiotropic developmental defects in humans.	These	findings	reveal an 
important role of lysosomal signalling in controlling embryonic cell fate transitions.  
Lysosomes are crucial for cellular homeostasis, and their function is under transcriptional 
feedback control by Tfe/Mitf transcription factors 23,34. Absence of amino acids upon 
cellular starvation locks the heterodimeric RagA/B-C/D-complex in a guanine nucleotide 
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loading conformation unable to recruit and activate mTORC1 at the lysosomal 
membrane. This, in turn, leads to nuclear translocation of Tfe/Mitf proteins and 
transcription of metabolic target genes 22 (Extended Data Fig. 5d). Exit from ESC self-
renewal, in contrast, depends on GDP-loading of RagC/D by Flcn, but not on the RagA/B 
nucleotide status, mTOR activity nor presence of Tfeb or Mitf, making it mechanistically 
distinct from amino acid sensing. Consistent with such an alternative pathway, 
hyperactivation of mTORC1 in Tsc2 KO cells phenocopies Flcn and Ragulator mutants 
upstream of RagC/D-GDP and Tfe3. Loss of Tsc2 and Flcn also predispose patients for 
renal carcinogenesis 35 and induce nuclear Tfe protein translocation in cancer cell lines 
25,36. Furthermore, patients with Tfe3 mutations present classical features of	hyperactive	
mTORC1	 pathway-related	 disorders	 37 (epilepsy, frequently associated with cortical 
malformations) (Supplementary Table 3). Ragulator is the major guanine nucleotide 
exchange factor (GEF) and, consequently, activator of RagA/B 14. However, ectopic 
lysosomal RagC in the absence of a functional Ragulator complex is sufficient for 
cytoplasmic Tfe3 localization and differentiation of ESCs. Furthermore, RagA/B is 
dominantly contributing to mTORC1 binding and activation compared to RagC/D 38,39, 
but Tfe3 interacts specifically with RagC/D-GDP. We therefore speculate that 
hyperactive mTORC1 competes with Tfe3 for binding to the Rag heterodimer. 
Mechanistically, we have identified a cytoplasmic inactivation domain within Tfe3 that 
contains all five identified patient mutations and is frequently deleted in renal cell 
carcinoma associated Tfe3 translocations. We predict this domain to form a RagC/D-
GDP binding fold and note that it overlaps with a conserved amino acid stretch specific 
to Tfe/Mitf transcription factors (Fig. 4a). Tfe3 is the predominant family member 
expressed in ESCs, but overexpression of a constitutive nuclear Tfeb allele is sufficient 
to impair exit from self-renewal (data not shown), thus showing functional redundancy 
between Tfe/Mitf family members and directly explaining the Tfe3 specificity observed 
in ESCs.  
Our findings show that lysosome activity controls ESC differentiation through RagC/D 
and Tfe3. Genes deregulated by Myc-inhibition, which mimics biosynthetic dormancy in 
diapause 11, also overlap with a subset of lysosomal Tfe3-targets in ESCs (Extended Data 
Fig. 2e). We therefore speculate that lysosomal signalling acts as a metabolic 
differentiation checkpoint that anticipates energy requirements faced during 
developmental progression. Alternatively, and not mutually exclusive, lysosome activity 
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may guide the remodelling of differentiation-specific gene regulatory networks. The 
latter would be consistent with the dynamic regulation of Tfe3 subcellular localization 
and lysosomal content during blastocyst development 3,4,6,40. Noteworthy, Tfe3-regulation 
discriminates lysosome activity from other metabolic inputs such as the tricarboxylic acid 
cycle that permissively provides substrates for genome-wide chromatin modifications 41. 
Importantly, nuclear Tfe3 antagonizes the downregulation of lysosome regulators during 
differentiation, which is congruent with general metabolic feedback regulation by 
Tfe/Mitf transcription factors 22 and is, likely, reflected in lysosomal storage	disorder	
related	 phenotypes	 in most individuals harbouring Tfe3 mutations (coarse	 facial	
features,	 umbilical	 hernia,	 postnatal	 growth	 retardation,	 obesity,	 hepatomegaly	 and	
hypoglycemia). Since Tfe3 acts as a transcriptional activator, we surmise that the 
concomitant suppression of developmental programs is consequential to direct metabolic 
targets. This	suggests	that Tfe3-dependent metabolic remodelling is important for steady 
state homeostasis and instructive to exit from pluripotency. 
Subcellular Tfe3 distribution is associated with developmental progression	of	human	
pluripotent	stem	cells	5,7.	It,	thus,	might	seem	surprising	that	ectopic	nuclear	Tfe3	is	not	
lethal	in	patients.	This,	however,	is	probably	a	consequence	of	mosaicism,	since	Tfe3	is	
an	X	chromosome	linked	gene:	Genetic	mosaicism	by	postzygotic	TFE3	mutation	in the 
only male patient, likely functional	mosaicism	by	random	X	chromosome	inactivation	in	
three	female	patients	(demonstrated	for	one	patient)	and	skewed X inactivation in one 
patient without hypopigmentation (patient 5). These mosaicisms are thus in line with the 
necessity for Tfe3 inactivation in early human development. Clinically, cutaneous 
pigmentary mosaicism, coarse features and	unspecific	syndromic	 ID	are	recognizable,	
and	 broadening	 of	 the	 phenotypic	 spectrum	 by	 the	 identification	 of	 more	 patients	
appears	 likely.	 In	 addition	 to	 regulating	embryogenesis,	mosaic	TFE3	mutations	may	
thus	be	considered	causative	to	ID.	
 In summary, our findings suggest that cellular metabolism instructs developmental 
progression in ESCs by a lysosomal Flcn-Ragulator-RagC/D-Tfe3 signalling axis. 
Despite shared molecular players this mechanism is distinct to amino acid dependent 
mTORC1-regulation, indicating repurposing of an ancient metabolic sensor conserved in 
yeast 18 for controlling transcriptional remodelling during cell fate transition. The 
identification of Tfe3 alleles insensitive to this lysosome-mediated inactivation in a novel 
34	
human developmental disorder demonstrates functional conservation and importance to 
disease, but also identifies opportunities for targeted intervention.	
 
Acknowledgments	
We	would	like	to	thank	the	patients	and	families	who	participated	in	this	study.	We	
also	thank	the	University	of	Burgundy	Centre	de	Calcul	(CCuB)	for	technical	support	
and	management	of	the	informatics	platform.	We	are	grateful	to	S.	Dessus-Babus,	K.	
Jacobeit	and	T.	Roloff	(FMI)	for	processing	sequencing	samples;	L.	Gelman	(FMI)	for	
imaging	assistance;	H.	Gut	(FMI)	for	performing	structural	modelling;	M.	Flemr	(FMI)	
for	advice	on	genome	editing;	J.Chao	(FMI),	A.Smith	(University	of	Cambridge),	
F.Stewart	(University	of	Dresden),	K.Yusa	(Wellcome	Trust	Sanger	Institute,	Hinxton),		
and	M.Leeb	(University	of	Vienna)	for	providing	reagents;	and	S.	Gasser,	P.	Liberali,	A.	
Peters,		D.	Schuebeler,	N.	Thomae	(FMI)	and	D.	Teis	(University	of	Innsbruck)	for	
comments	on	the	manuscript.	This	work	was	funded	by	an	EMBO	long	term	fellowship	
(to	D.O.),	the	Programme	Hospitalier	de	Recherche	Clinique	(PHRC)	National	(to	P.V.),	
the	Regional	Council	of	Burgundy	and	the	Centre	Hospitalo-Universitaire	de	Dijon	(to	
L.F.)	(PARI	2015),	and	the	Novartis	Research	Foundation	(to	J.B.).	
		
	
Author	contribution	
F.V.,	M.R.	M.A.,	L.D.J.,	J.S-O.	and	T.J.	performed	experiments.	D.M.,	M.S.,	Y.D.,	P.K.,	J.T.,	
K.L.I.VG.	 and	 S.VK.	 performed	 bioinformatic	 analysis.	 M.Z.	 and	 D.O.	 executed	 the	
CRIPSR/Cas9	screen.	D.H.	performed	mass	spectrometry.	P.V.,	J-M.D.B.,	F.D.,	D.G.,	N.H.,	
K.D.L.,	C.T.R.,	M.VH.	recruited	and	evaluated	the	patients.	S.S.	established	quantitative	
gRNA	sequencing.	L.F.,	J-B.R.	and	J.B.	supervised	the	work.	D.L.	and	J.B.	wrote	the	paper.	
	
Conflict	of	interest	statement	
The	authors	declare	no	conflict	of	interest. 	
35	
References 
 
1. Martello, G. & Smith, A. The nature of embryonic stem cells. Annu. Rev. Cell Dev. 
Biol. 30, 647–675 (2014). 
2. Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C. & Yusa, K. Genome-
wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide 
RNA library. Nat. Biotechnol. 32, 267–273 (2014). 
3. Kalkan, T. et al. Tracking the embryonic stem cell transition from ground state 
pluripotency. Development 144, 1221–1234 (2017). 
4. Betschinger, J. et al. Exit from pluripotency is gated by intracellular redistribution of 
the bHLH transcription factor Tfe3. Cell 153, 335–347 (2013). 
5. Takashima, Y. et al. Resetting transcription factor control circuitry toward ground-
state pluripotency in human. Cell 158, 1254–1269 (2014). 
6. Geula, S. et al. Stem cells. m6A mRNA methylation facilitates resolution of naïve 
pluripotency toward differentiation. Science 347, 1002–1006 (2015). 
7. Gafni, O. et al. Derivation of novel human ground state naive pluripotent stem cells. 
Nature 504, 282–286 (2013). 
8. Westerman, B. A. et al. A genome-wide RNAi screen in mouse embryonic stem cells 
identifies Mp1 as a key mediator of differentiation. J. Exp. Med. 208, 2675–2689 (2011). 
9. Hayashi, K., Ohta, H., Kurimoto, K., Aramaki, S. & Saitou, M. Reconstitution of the 
mouse germ cell specification pathway in culture by pluripotent stem cells. Cell 146, 
519–532 (2011). 
10. Boroviak, T. et al. Lineage-Specific Profiling Delineates the Emergence and 
Progression of Naive Pluripotency in Mammalian Embryogenesis. Dev. Cell 35, 366–
382 (2015). 
11. Scognamiglio, R. et al. Myc Depletion Induces a Pluripotent Dormant State 
Mimicking Diapause. Cell 164, 668–680 (2016). 
12. Bulut-Karslioglu, A. et al. Inhibition of mTOR induces a paused pluripotent state. 
Nature (2016). doi:10.1038/nature20578 
13. Buecker, C. et al. Reorganization of enhancer patterns in transition from naive to 
primed pluripotency. Cell Stem Cell 14, 838–853 (2014). 
14. Bar-Peled, L., Schweitzer, L. D., Zoncu, R. & Sabatini, D. M. Ragulator is a GEF for 
the rag GTPases that signal amino acid levels to mTORC1. Cell 150, 1196–1208 (2012). 
15. Bar-Peled, L. & Sabatini, D. M. Regulation of mTORC1 by amino acids. Trends Cell 
Biol. 24, 400–406 (2014). 
16. Tsun, Z.-Y. et al. The folliculin tumor suppressor is a GAP for the RagC/D GTPases 
that signal amino acid levels to mTORC1. Mol. Cell 52, 495–505 (2013). 
17. Tsun, Z.-Y. et al. The Folliculin Tumor Suppressor Is a GAP for the RagC/D 
GTPases That Signal Amino Acid Levels to mTORC1. Mol. Cell (2013). 
doi:10.1016/j.molcel.2013.09.016 
18. Péli-Gulli, M.-P., Sardu, A., Panchaud, N., Raucci, S. & De Virgilio, C. Amino Acids 
Stimulate TORC1 through Lst4-Lst7, a GTPase-Activating Protein Complex for the Rag 
Family GTPase Gtr2. Cell Rep 13, 1–7 (2015). 
19. Nada, S. et al. The novel lipid raft adaptor p18 controls endosome dynamics by 
anchoring the MEK-ERK pathway to late endosomes. EMBO J. 28, 477–489 (2009). 
20. Sano, O. et al. Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via 
PIKfyve inhibition. FEBS Lett. 590, 1576–1585 (2016). 
21. Martina, J. A. & Puertollano, R. Rag GTPases mediate amino acid-dependent 
recruitment of TFEB and MITF to lysosomes. J. Cell Biol. 200, 475–491 (2013). 
36	
22. Raben, N. & Puertollano, R. TFEB and TFE3: Linking Lysosomes to Cellular 
Adaptation to Stress. Annu. Rev. Cell Dev. Biol. 32, 255–278 (2016). 
23. Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and 
regulates the lysosome via mTOR and TFEB. EMBO J. 31, 1095–1108 (2012). 
24. Roczniak-Ferguson, A. et al. The transcription factor TFEB links mTORC1 signaling 
to transcriptional control of lysosome homeostasis. Sci Signal 5, ra42–ra42 (2012). 
25. Peña-Llopis, S. et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 
30, 3242–3258 (2011). 
26. Li, Y. et al. Protein kinase C controls lysosome biogenesis independently of 
mTORC1. Nat. Cell Biol. 18, 1065–1077 (2016). 
27. Medina, D. L. et al. Lysosomal calcium signalling regulates autophagy through 
calcineurin and TFEB. Nat. Cell Biol. 17, 288–299 (2015). 
28. Dutta, D. et al. Self-renewal versus lineage commitment of embryonic stem cells: 
protein kinase C signaling shifts the balance. Stem Cells 29, 618–628 (2011). 
29. Kauffman, E. C. et al. Molecular genetics and cellular features of TFE3 and TFEB 
fusion kidney cancers. Nat Rev Urol 11, 465–475 (2014). 
30. Grabiner, B. C. et al. A diverse array of cancer-associated MTOR mutations are 
hyperactivating and can predict rapamycin sensitivity. Cancer Discov 4, 554–563 (2014). 
31. Mirzaa, G. M. et al. Association of MTOR Mutations With Developmental Brain 
Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary 
Mosaicism. JAMA Neurol 73, 836–845 (2016). 
32. Sybert, V. P. Hypomelanosis of Ito: a description, not a diagnosis. J. Invest. 
Dermatol. 103, 141S–143S (1994). 
33. Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nat. 
Methods 12, 7–8 (2015). 
34. Martina, J. A. et al. The nutrient-responsive transcription factor TFE3 promotes 
autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal 7, ra9–ra9 
(2014). 
35. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: 
a metabolic disease. Nat Rev Urol 7, 277–285 (2010). 
36. Petit, C. S., Roczniak-Ferguson, A. & Ferguson, S. M. Recruitment of folliculin to 
lysosomes supports the amino acid-dependent activation of Rag GTPases. J. Cell Biol. 
202, 1107–1122 (2013). 
37. Parrini, E., Conti, V., Dobyns, W. B. & Guerrini, R. Genetic Basis of Brain 
Malformations. Mol Syndromol 7, 220–233 (2016). 
38. Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino acid signaling to 
mTORC1. Science 320, 1496–1501 (2008). 
39. Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P. & Guan, K.-L. Regulation of 
TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 10, 935–945 (2008). 
40. Tsukamoto, S. et al. Functional analysis of lysosomes during mouse preimplantation 
embryo development. J. Reprod. Dev. 59, 33–39 (2013). 
41. Carey, B. W., Finley, L. W. S., Cross, J. R., Allis, C. D. & Thompson, C. B. 
Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 
518, 413–416 (2015). 
 
 
 
37	
 
 
Figure 1: Identification of differentiation drivers in a CRISPR/Cas9 screen. 
(a) Schematic outline of the screening procedure. Green indicates Rex1 expression. 
(b) Screen results ordered by statistical significance. Genes labeled with red were 
retested, of which genes annotated in black were validated.  
(c) Tfe3 localization in RGd2 cells transiently transfected with Cas9 and gRNAs 
targeting indicated genes after 3-5 passages upon 2i withdrawal. Note that control cells 
are expectedly lost during the procedure due to terminal differentiation. 
(d) Resistance to differentiation of Oct4GIP ESCs transfected with indicated siRNA 
combinations after 3 days (d) of 2i withdrawal. Results were normalized to negative 
(neg) siRNA cells. Average and standard deviation (SD) of 2 technical replicates. 
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(e) Retention of self-renewal in 2i after 2d of differentiation in indicated conditions. 
Average and SD of 3 biological replicates.	  
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Figure	2:	Transcriptional	programs	controlled	by	Flcn-Lamtor1-Tfe3.	
(a)	k-means	clustering	of	 log2	 fold	changes	of	 transcripts	significantly	deregulated	 in	
ESCs	of	indicated	genotypes.	
(b)	 PCA	 analysis	 of	 indicated	 samples.	 Note	 that	 PC1	 distinguishes	 experimental	
variations	between	studies.	
(c)	 k-means	 clustering	 of	 centred	 expression	 in	 ESCs	 and	 during	 differentiation	 of	
indicated	genotypes,	 and	 top	 five	GO	 term	enrichments	of	 gene	 clusters	12	and	13.	
Samples	(columns)	were	ordered	by	hierarchical	clustering	(dendrogram	shown	below	
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the	 heatmap).	 Transcripts	 dynamically	 regulated	 during	wildtype	 ESC	 differentiation	
and	specifically	deregulated	during	differentiation	of	Tfe3-ERT2	Tam-treated	and	Flcn	
KO	cells	were	considered.	 	
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Figure	3:	Mechanistic	dissection	of	lysosomal	signalling	in	ESCs.		
(a)	Colocalization	of	Lamtor1,	RagC	and	tagged	Flcn	with	LAMP1	(arrowheads)	in	ESCs.	
(b-d)	Tfe3	localization	(b)	and	retention	of	self-renewal	after	3d	of	2i	withdrawal	in	LT1	
KO.1	(c)	and	Flcn	KO.1	(d)	cells	expressing	indicated	Rag	transgenes.	Average	and	SD	of	
2	biological	replicates.	
(e,f)	Retention	of	self-renewal	in	wildtype	cells	expressing	indicated	Rag	transgenes	(e)	
and	indicated	cell	lines	(f)	differentiated	for	3d	in	the	absence	or	presence	of	100nM	
Vacuolin-1.	Average	and	SD	of	2	technical	replicates.	
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(g,h)	 Tfe3	 interactome	 in	 ESCs.	 Red	 denotes	 highly	 significant	 enriched	 proteins,	 of	
which	 blue	 marks	 14-3-3	 protein	 family	 members	 and	 yellow	 v-ATPase	 subunits.	
Quantification	is	based	on	3	biological	replicates.	
(i,j)	Tfe3	localization	(i)	and	retention	of	self-renewal	after	3d	of	2i	withdrawal	(j)	in	Tfe3	
KO.6	 cell	 lines	 conditionally	 expressing	 indicated	 Tfe3	 alleles.	 Average	 and	 SD	 of	 2	
biological	replicates.	
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Figure	4:	Disease-associated	nuclear	Tfe3	gain	of	function	alleles.	
(a)	Tfe3	domain	and	exon	structure,	and	Tfe3	deletion	constructs	used	in	(b)	and	(c).	
Exons	3	and	4,	and	the	Tfe/Mitf	transcription	factor	family	specific	homology	stretch	are	
indicated.	
(b,c,e,f)	Tfe3	localization	(b,e)	and	retention	of	self-renewal	after	3d	of	2i	withdrawal	
(c,f)	in	Tfe3	KO.6	cell	lines	conditionally	expressing	indicated	Tfe3	alleles.	Average	and	
SD	of	2	biological	replicates.	
(d)	 Clinical	 phenotype	 of	 patients	 and	 molecular	 details	 of	 corresponding	 TFE3	
mutations.	I-IV:	Facial	features	of	patient	1	(I),	2	(II),	3	(III)	and	5	(IV).	Note	the	coarse	
features,	 facial	 hypertrichosis	 and	 full	 cheeks	 common	 to	 the	 individuals.	 V-VIII:	
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Cutaneous	phenotype	of	patient	1	(V),	2	(VI,VII)	and	3	(VIII).	Note	the	whorls	and	streak	
hypopigmentation	along	Blaschko’s	line.	IX:	Body	asymmetry,	umbilical	hernia	in	Patient	
4.	
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Extended	 Data	 Figure	 1:	 Characteristics	 of	 loss	 of	 function	 in	 lysosomal	 signalling	
components.	
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(a)	 MAGeCK	 scores	 and	 p-values	 of	 top	 19	 screen	 hits,	 including	 validation	
(phenotypically	scoring	gRNAs/all	gRNAs	tested).	
(b)	Tfe3	localization	in	long	term	differentiated	RGd2	cells	transiently	transfected	with	
Cas9	and	gRNAs	targeting	indicated	genes.	
(c)	Resistance	to	differentiation	of	Oct4GIP	ESCs	transfected	with	indicated	siRNAs	after	
3d	of	2i	withdrawal.	Results	were	normalized	to	negative	(neg)	siRNA	cells.	Average	and	
SD	of	2	technical	replicates.	
(d)	 Deconvolution	 of	 siRNA	 pools	 in	 O4GIP	 ESC	 commitment	 assay	 after	 3d	 of	
differentiation.	 Results	 were	 normalized	 to	 neg	 siRNA	 cells.	 Average	 and	 SD	 of	 2	
technical	replicates.	(p)	denotes	pool	of	4	siRNAs.	Note	that	the	Lamtor3	siRNA	pool	has	
been	deconvoluted	before4.	
(e)	Nucleo-cytoplasmic	Tfe3	ratios	in	O4GIP	ESCs	transfected	with	indicated	siRNAs.	
(f)	CRISPR/Cas9	mutants	generated	 in	this	study.	Location	of	gRNAs	 is	 indicated	with	
blue	bars.	Red	bars	indicate	location	of	Tfe3	gRNAs	recovered	in	the	primary	screen.	(+)	
indicates	mutation	of	ATG	Start	codons,	(*)	generation	of	 in	frame	STOP	codons	and	
dashed	lines	exon	skipping.	
(g)	Absence	of	Tfe3	immunoreactivity	in	Tfe3	KO	ESC	clones.	Insets	are	DNA	staining	of	
the	field	of	view.	
(h)	Tfe3	localization	in	2i	and	after	24h	of	2i	withdrawal	in	indicated	cell	lines.	
(i)	 Alkaline phosphatase composition of colonies derived from indicated long term 
differentiated cell lines subjected to clonal self-renewal in 2i.	
47	
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Extended	Data	Figure	2:	Analysis	of	RNA	sequencing	data.	
(a)	Scatter	plot	of	log2fold	changes	compared	to	wildtype	controls	in	Flcn	and	LT1	KO	
ESCs.	
(b)	 Top	 five	 gene	 ontology	 (GO)	 term	 enrichments	 in	 gene	 clusters	 1-11	 (Fig.	 2a,c).	
Clusters	1-6	contain	early	and	late	Tfe3	target	genes	after	34h Tam induction in Tfe3-
ERT2 ESCs. Clusters 3-6 contain genes congruently altered in Flcn and Lamtor1 KO 
ESCs, while clusters 7 and 8 are specific to KO ESCs, suggesting the presence of indirect 
targets and adaption to Tfe3 activation in established KO ESC lines. Clusters 9 and 10 
contain genes whose regulation during differentiation is largely unaffected by genetic 
perturbations. Genes in cluster 11 are specifically upregulated in acute but not long-term 
differentiated Tam-treated Tfe3-ERT2 or KO cells and are unchanged during wildtype 
differentiation. This cluster of genes behaves similar to cluster 2, also with respect to GO 
terms enrichment, and likely reflects transiently induced Tfe3-targets. 
(c,	 f)	 Pearson’s	 correlation	 coefficients	 of	 pairwise	 comparisons	 between	 log2fold	
changes	 of	 indicated	 samples.	 Adaption	 to	 Tfe3	 activation	 is	 reflected	 in	 a	 higher	
correlation	of	transcriptional changes in Flcn and Lamtor1 KO cells with 34h compared 
to 3h Tam treated Tfe3-ERT2 ESCs (c). Changes in differentiating wildtype cells 34h 
after 2i withdrawal correlate with those reported in the ESC to EpiLC and the E4.5 to 
E5.5 epiblast (Epi) transition (f). Inner cell mass (ICM), morula (Mor).	
(d)	Mean	density	of	Tfe3	ChIP-Seq	alignments	in	wildtype	ESCs	at	transcriptional	start	
sites	(TSSs)	of	upregulated	genes	upon	indicated	genetic	perturbations.	Consistent	with	
indirect	Tfe3	targets,	TSSs of genes induced after 3h Tam treatment had a higher average 
Tfe3 occupancy when compared to upregulated genes in other samples.	 (ns)	 indicates	
non-significantly	changed	control	transcripts.		
(e)	Scatter	plot	of	 log2fold	changes	compared	to	respective	wildtype	controls	 in	34h	
Tam-treated	 Tfe3-ERT2	 ESCs	 and	 Myc	 inhibitor	 treated	 ESCs.	 GO	 term	 enrichment	
identifies	an enrichment of lysosome function	in	genes	significantly	deregulated	in	both	
conditions.	
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Extended	Data	Figure	3:	Functional	analysis	of	lysosomal	signalling.		
(a,b)	Tfe3	localization	(a)	and	retention	of	self-renewal	after	3d	of	2i	withdrawal	(b)	in	
Flcn	 KO.1	 cells	 expressing	 indicated	 Rag	 transgenes.	 Average	 and	 SD	 of	 2	 technical	
replicates.	
(c)	 Subcellular	 localization	 of	 RagC	 and	 Lamtor1	 in	 O4GIP	 ESCs	 transfected	 with	
indicated	 siRNAs.	 Insets	 are	 DNA	 staining	 of	 the	 field	 of	 view.	 Note	 cytoplasmic	
delocalization	of	RagC	upon	knockdown	of	Lamtor1,	2	and	3	but	not	Flcn	or	Tsc2.	
(d)	Subcellular	 localization	of	RagC	and	LAMP1	in	LT1	KO.1	ESCs	expressing	indicated	
constructs.	Note	rescue	of	lysosomal	RagC	localization	upon	Lamtor1	expression,	and	
cytoplasmic	 and	 lysosomal	 RagC	 localization	 of	 overexpressed	 RagC	 and	 LTS-RagC,	
respectively.	
(e,f)	Tfe3	localization	(e)	and	retention	of	self-renewal	after	3d	of	2i	withdrawal	(f)	in	
wildtype	 cells	 expressing	 indicated	 RagC	 transgenes.	 Average	 and	 SD	 of	 2	 biological	
replicates.	
(g)	Alkaline	phosphatase	staining	of	wildtype	cells	expressing	indicated	RagC	transgenes	
and	transfected	with	indicated	siRNAs	replated	after	3d	of	differentiation	in	2i.	
(h)	Resistance	to	differentiation	of	Oct4GIP	ESCs	differentiated	for	3d	in	the	presence	
of	 AZD8055	 (AZD,	 200nM,	 100nM,	 50nM,	 25nM),	 Rapamycin	 (Rapa,	 80nM,	 40nM,	
20nM,	10nM),	BafA	 (2.5nM,	1.25nM),	ConA	 (20nM,	10nM,	5nM,	2.5nM),	Vacuolin-1	
(400nM,	200nM,	100nM,	50nM)	and	Chloroquine	(20µM,	10µM,	5µM,	2.5µM)).	Results	
were	normalized	to	control	cells.	Average	and	SD	of	2	technical	replicates.	
(i)	Self-renewal	of	wildtype	cells	in	2i	after	24h	treatment	with	40nM	Rapamycin,	100nM	
AZD8055,	20nM	ConA,	100nM	Vacuolin-1	and	10µM	Chloroquine	 in	 the	presence	or	
absence	of	2i.	Average	and	SD	of	two	technical	replicates.	
(j)	Tfe3,	RagC	and	LAMP1	localization	in	ESCs	treated	for	24h	with	100nM	Vacuolin-1.	
Arrowheads	indicate	colocalization	of	RagC	and	LAMP1.	
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Extended	 Data	 Figure	 4:	 mTORC1	 hyperactivation,	 but	 not	 inhibition,	 impairs	
differentiation.	
(a,g,k,m)	 Tfe3	 subcellular	 localization	 in	 wildtype	 ESCs	 treated	 for	 24h	 with	 2.5µM	
Gö6983	(a),	in	wildtype	ESCs	cultured	for	2d	with	and	without	amino	acids	(aa)	(g),	in	
indicated	 cell	 lines	 in	 the	 presence	 of	 20nM	 Rapamycin	 (k),	 and	 in	 Tsc2	 KO.1	 ESCs	
expressing	indicated	Rag	constructs	(m).	
(b,h,j,l)	Retention	of	self-renewal	after	3d	 in	N2B27	(b,j,l)	or	2d	 in	 indicated	nutrient	
conditions	(h)	of	wildtype	cells	(h)	or	Tsc2KO.1	cells	(j,l)	expressing	indicated	transgenes	
(b,h,l)	or	Tfe3KO.8	cells	(h)	in	the	presence	of	2.5µM	Gö6983	(b)	or	20nM	Rapamycin	
(j).	Average	and	SD	of	2	technical	(b),	2	biological	(j,l)	or	3	biological	(h)	replicates.	
(c,d,e)	 Resistance	 to	 differentiation	 in	 O4GIP	 ESCs	 transfected	with	 indicated	 siRNA	
combinations	and	treated	with	20nM	Rapamycin	and	50nM	AZD8055	(e)	after	3d	of	2i	
withdrawal.	Results	were	normalized	to	neg	siRNA	cells.	Average	and	SD	of	2	technical	
replicates.	
(f,i)	Western	blot	analysis	of	mTORC1	targets	in	ESCs	and	48h	after	2i	withdrawal	(f)	and	
in	indicated	ESC	lines	(i).	20nM	Rapamycin	was	added	where	indicated.	
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Extended	Data	Figure	5:	Secondary	structure	prediction	of	the	Tfe3	inactivation	domain	
and	model.	
(a,b)	Tfe3	localization	(a)	and	retention	of	self-renewal	after	3d	of	2i	withdrawal	(b)	in	
Tfe3Δexon	4	cells.	Average	and	SD	of	2	technical	replicates.	
(c)	 Amino	 acid	 sequence	 alignment	 of	 the	 exon3-4	 boundary	 in	mouse	 and	 human	
Tfe/Mitf	 family	 members.	 I-Tasser	 secondary	 structure	 prediction	 with	 confidence	
values	is	indicated.	Patient	mutation	homologues	are	highlighted	in	red.	
(d)	Model	summarizing	lysosomal	signalling	in	ESC	differentiation	and	comparison	with	
mTORC1-dependent	amino	acid	sensing.	 	
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Supplementary	Table	1:	Results	of	CRISPR/Cas9	screen,	normalized	read	counts,	data	
illustrated	in	Fig.	1b,	2,	Extended	Data	Fig.	1a	and	2.	
	
Supplementary	Table	2:	Quantitative	mass	spectrometry,	data	illustrated	in	Fig.	3g	
and	h.	
	
Supplementary	Table	3:	Clinical and molecular features of the six patients with a TFE3 
mutation.	Characteristics, inheritance, frequency in the public database ExAC and 
prediction scores regarding pathogenicity (Polyphen 
http://genetics.bwh.harvard.edu/pph2/, Grantham and CADD scores) of mutations.	
	
Supplementary	Table	4:	Oligonucleotide	Sequences,	siRNAs,	sequencing	datasets.	 	
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Extended	Clinical	Data:	Description	of	clinical	history	and	phenotypes	of	patients	with	
TFE3	mutations.	
 
We identified two germline de novo missense variants (NM_006521.4:c.356A>C 
p.(Q119P) and NM_006521.3:c.602A>C; p.(Q201P) in the X-linked gene TFE3 in two 
unrelated females (Patient 1 and 2), who shared a similar phenotype of severe intellectual 
disability (ID) and hypopigmentation on Blaschko’s lines (clinical pictures are 
summarized in Table S3). The eldest patient had in addition coarse facial features, 
frontonasal dysplasia, obesity, epilepsy and growth retardation. We thus activated 
datasharing through GeneMatcher 1, and recruited two additional individuals with 
pigmentary mosaicism and a de novo missense TFE3 variant. One was a 3 years old 
female with severe ID, hypopigmentation, epilepsy and coarse facial features, who 
harbored a germline TFE3 variant (NM_006521.5:c.560C>T, p.T187M). The other one 
was a 5 years old male with severe ID, growth retardation, epilepsy, hypopigmentation 
and a neonatal history of cholestasis, hepatomegaly and hypoglycemia, in whom WES 
identified a de novo mosaic TFE3 variant (NM_006521.5:c.560C>G, p.T187R), 
supported by around 65% of sequencing reads in the blood. Finally, we identified a fifth 
female adult patient with a de novo germline missense TFE3 variant 
(NM_006521.4:c.557C>T p.P186L) in our local diagnostic WES cohort. She presented 
with a similar phenotype of severe ID, epilepsy, growth retardation, obesity, and coarse 
facial features with facial hypertrichosis, but did not have pigmentation anomaly; she had 
been suspected of a storage disorder. Complementary DNA analysis for patient 1, 2 and 
5 revealed that the allele carrying the TFE3 mutation was supported by respectively 89%, 
91% and 95% of the reads. X-inactivation studies showed a random X-inactivation (29-
69%) in the non-cultured fibroblasts of the first patient; and a biased X-inactivation (85-
15%) in the fibroblasts of the fifth patient. 
The first patient was the first child of non-related parents. The family history was 
unremarkable except for a labial pit in her mother and a unilateral cleft lip and palate in 
her maternal grandfather. Antenatal karyotype was performed due to high serum markers, 
which showed a normal result. She was born at 34 weeks of gestation, with normal birth 
weight (30th centile) and length (60th centile). Examination revealed bilateral cleft lip and 
palate, hypo-pigmented areas on the back along Blaschko’s lines, and a bilateral hip 
dislocation. Because of the cleft lip and palate in the context of the family history, Van 
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Der Woude syndrome was suspected; IRF6 testing by Sanger sequencing was negative. 
Early milestones were reported as normal until 7 months, when she developed 
generalized epilepsy and psychomotor regression.  When she was referred to a clinical 
geneticist, at 14 years, she had severe intellectual disability. She could not walk 
independently, had no speech. She had growth retardation, with length at -4.5 S.D. and 
obesity (body mass index (BMI) +3 S.D.). OFC was average. Orthopedic examination 
showed slightly asymmetric and short lower limbs, flat feet and hyperlordosis. Facial 
dysmorphism was striking with bifid nose, hypertelorism, hypertrichosis and coarse 
features. Echocardiography demonstrated asymptomatic aortic insufficiency. 
The second patient was the first child born from unrelated parents. The mother has 
deafness as well as her two brothers. Pregnancy was marked by the discovery of ureteral 
dilatation at 5 months of gestation in a context of maternal gestational diabetes. She was 
born at 36 weeks of gestation, with fetal macrosomia (weight 99th p., length 90th p. 
occipitofrontal circonference 95th p.). She presented with neonatal hypotonia and feeding 
difficulties. She sat at 12 months of age. At last examination at 4 years and 3 months of 
age she was unable to stand and walk alone, had no speech. She presented sleep 
disturbance and hand stereotypies. Her weight was +1.5 SD, length was +2.5 SD with a 
parental target size at +1.2 SD and her OFC was +1 SD. BMI was 15.4 (mean). Brain 
MRI, skeletal X-rays, eye and auditive exams were normal. 
The third female was referred for suspicion of incontinentia pigmenti. She was the first 
child of nonrelated healthy parents. Pregnancy was complicated by oligohydramnios and 
third trimester intra-uterine growth retardation. She was born at 41 weeks of gestation 
with a low birthweight on the 2nd percentile, and was admitted for hypoglycemia in the 
first two weeks of life. At 6 months she was noted to have delayed milestones and a poor 
eye contact. She developed tonic seizures from 18 months. Brain MRI brain was normal, 
EEG showed an abnormal pattern with epileptic encephalopathy and multifocal spikes. 
She had chronic upper airway infections in the winter, periods during which the parents 
reported she did not make any developmental progress or even regressed. At examination 
at 3 years old, she could roll over but could not walk or grasp objects; she made sounds 
but no words. She had linear and whorled hyperpigmentation all over the body except on 
the face, palms and soles. Growth parameters were in the normal ranges. She was noted 
to have umbilical hernia, strabismus and a single palmar crease. The facial features were 
remarkable by synophris, hypertrichosis, full cheeks and lips, flat nasal bridge, 
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hypertelorism and thick eyebrows. In the context of the pigmentary changes, 
chromosomal mosaicism was considered, and a skin biopsy was performed, showing a 
mosaic translocation t(X;11) with a microdeletion of Xp22.3  in 1 out of 2 cell-cultures. 
However, as the deletion contained no genes of which haploinsuffiency was known to 
cause developmental delay and seizures, trio-WES was initiated on the blood, after 
parental consents.  
The fourth patient was a male, from unrelated parents with no family history. The 
pregnancy was unremarkable. He was born at term by caesarean section for fetal distress, 
with normal growth parameters and Apgar score at 8 and 9. He was admitted in the 
neonatal period for seizures on the first day of life, neonatal hypoglycemia, transient renal 
insufficiency, bronchomalacia, and cholestasis. Examination revealed hepatomegaly, 
hypotonia, umbilical and inguinal hernias. He had severely delayed milestones. When he 
was referred at 5 years old, he could not walk or speak, and had just developed epilepsy 
and hearing loss. He had pigmentation anomalies along Blaschko’s lines on trunk and 
back, asymmetric lower limbs with flat feet, growth retardation on -4.5 SD. Facial 
features were coarse, he had a flat nasal bridge. 
The fifth female patient had been included in the local diagnostic WES cohort because 
of severe ID and suspicion of storage disorder, despite normal results of extensive 
metabolic workup. She was the first child of unrelated parents, born at 39 weeks of 
gestation following an uneventful pregnancy. Birth weight was on 5th centile, length on 
10th centile, OFC on 10th centile. Neonatal examination showed bilateral clubfeet. Her 
first year of life was marked by recurrent infections and by rapid weight gain. 
Psychomotor development was normal until 9 months; she then made very slow progress, 
walked at 40 months, and then went in a school for children with special needs. She 
developed generalized epilepsy from 10 years old with tonic-clonic seizures. Behavioural 
issues were noted from teenage, treated by antipsychotic drug. On the last examination 
at 20 years old, she could speak a few words. Her weight was on +4 S.D., length -4 S.D, 
BMI 30. She had coarse facial features, hypertelorism, flat nasal bridge, anteverted nares, 
full mouth, thick gums, protruding tongue, facial hypertrichosis and convergent 
strabismus. Orthopedic examination showed hyperlordosis, limitation in elbow 
extension, genu valgum, flat feet, small hands and feet. Bone age on the X-ray, as well 
as the spine, were normal. Blood glucose level was normal, and there was no 
hepatomegaly on the abdominal ultrasound. 
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Materials	and	Methods	
	
Cell Culture  
ESCs (RGd2 containing a Rex1:GFPd2-IRES-Blasticidin reporter 1 (gift from Martin 
Leeb, Vienna), Oct4GIP 2, E14 (gift from Martin Leeb, Vienna)) were cultured on plastic 
coated with gelatin or laminin (Sigma) in N2B27 medium (DMEM/F12 (Life 
Technologies), Neurobasal (Gibco) supplemented with N2 (homemade) and B-27 
Serum-Free Supplement (Gibco), 1mM sodium pyruvate (Gibco), 2mM L-glutamine 
(Gibco), 0.1 mM 2-mercaptoethanol (Sigma)), and where indicated with 2i (3µM 
CHIR99021 and 1µM PD0325901 (Steward lab, Dresden)), knockout serum replacement 
(Gibco), Rapamycin (Cell Signaling), AZD8055 (Santa Cruz), BafilomycinA 
(Millipore), ConcanamycinA (Santa Cruz), Vacuolin-1 (Santa Cruz), Chloroquine 
(Sigma), Gö6983 (2.5µM, Sigma), Myc inhibitor (10058-F4, Sigma), 4-
hydroxytamoxifen (0.1µM, Sigma), Doxycycline (0.1µg/ml, Sigma), LIF,  FGF and 
ActivinA (Smith lab, Cambridge). For alkaline phosphatase assays (Sigma), cells were 
grown on laminin-coated plates, fixed, and stained according to the manufacturer’s 
instruction. For differentiation, ESCs were plated on gelatin-coated plates at 1.5 x 104 
cells/cm2 and, the following day, 2i was withdrawn. For EpiLC differentiation 3, 
knockout serum replacement (1%), FGF (12ng/ml) and ActivinA (20ng/ml) were 
additionally added. For starvation experiments, ESCs grown on plastic or glass plates 
were incubated in R-N2B27 (amino-acid free RPMI (homemade), supplemented with 
B27 and N2, and 3.8mg/ml glucose), supplemented with 2i and amino acids (Sigma; 
Glycine: 24.375 mg/l, L-Alanine: 3.225 mg/l, L-Arginine Hydrochloride: 115.75 mg/l, 
L-Asparagine: 4.165 mg/l, L-Histidine: 36.74 mg/l, L-Isoleucine: 79.735 mg/l, L-
Leucine: 82.025 mg/l, L-Lysine: 118.625 mg/l, L-Methionine: 23.62 mg/l, L-
Phenylalanine: 50.74 mg/l, L-Proline: 12.505 mg/l, L-Serine: 34.125 mg/l, L-Threonine: 
74.225 mg/l, L-Tryptophan: 12.51 mg/l, L-Tyrosine: 63.895 mg/l, L-Valine: 59.925 
mg/l, L-Glutamic acid: 3.675 mg/l, L-Cysteine: 8.78 mg/l, L-Cystine: 15.645 mg/l, L-
Aspartic acid: 3.325 mg/l) as indicated for 2d and differentiation was induced by 2i 
removal. siRNA (Supplementary Table 4) and plasmid transfections, and exit from self-
renewal of O4GIP and RGd2 ESCs was performed and quantified as described before 2. 
 
 
61	
Immunostaining 
Cell were seeded on laminin-coated 96well glass plates (Greiner Bio-One), fixation and 
immunostaining performed as described 2, and images were captured using a LSM 710 
scanning head confocal microscope (Zeiss). Primary antibodies used were anti-Flag 
(Sigma, F1804, 1:1000), anti-Lamp1 (DSHB, 1D4B, 1:500), anti-Lamtor1 (Cell 
signaling, 8975S, 1:500), anti-RagC (Cell signaling, 9480S, 1:100) and anti-Tfe3 (Sigma, 
HPA023881, 1:1000). Quantification of nucleo-cytoplasmic Tfe3 ratios using 
CellProfiler (Broad Institute) was performed as described 2. 
 
CRISPR/Cas9 screen  
Lentiviral gRNA libraries were generated in HEK293 cells. Stable Cas9 expressing 
female RGd2 ESC (gift from Martin Leeb, Vienna) clones were derived by transfecting 
with pPB-LR5.1-EF1a-hph2ACas9 (derived from pPB-LR5.1-EF1a-puro2ACas9, gift of 
Kosuke Yusa, Hinxton) and 7.2x106 cells of two independent clones were infected with 
the lentiviral gRNA library at a 20 fold coverage and multiplicity of infection of 0.25. 
Stable integrations were selected for 6d in the presence of 0.1 µg/ml Puromycin and 107 
cells for each clone were plated on Laminin-coated dishes in the absence of 2i, while 
2x107 were used for generation of input sequencing libraries. After 3d of differentiation, 
2x107 cells were passaged in N2B27 containing 1µg/ml Blasticidin to select for Rex1 
expression, and cells at passage 4 and 5 taken for generation of experimental sequencing 
libraries. Uninfected control cells were lost after the second passage. Genomic DNA was 
isolated using Proteinase K (Roche) digestion and phenol-chloroform extraction (Sigma).  
For gRNA sequencing, we developed an approach using unique molecular identifiers 
(UMIs) for accurate quantification. Biological replicates were divided into aliquots of 
500ng genomic DNA (input samples: 8µg total; selected samples: 2µg total). An oligo 
nucleotide containing UMIs and the 3' part of the Illumina P5 sequence (5'-
TCCCTACACGACGCTCTTCCGATCTN(5-
9)TCTTGTGGAAAGGACGAAACACC-3') was integrated using Phusion DNA 
polymerase (Thermo Fisher Scientific) in a single round of denaturation, annealing 
(62°C) and extension. Then 2µl of exonuclease I (NEB) were added and incubated at 
37°C for 45min, followed by heat inactivation and purification using AMPure XP beads 
(Agencourt) with a 1:1 ratio. gRNAs were amplified using Phusion DNA polymerase for 
25 cycles (Fwd: 5'-TCCCTACACGACGCTCTTCCGATCT-3'; Rev: 5'-
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GTTCAGACGTGTGCTCTTCCGATCTCTTGTGTAGCGCCAAGTGCC-3'; 
annealing temperature of 64°C)) and purified using AMPure XP beads (1:1 ratio, elution 
in 22µl). 5µl were used in an Illumina indexing PCR reaction using Phusion DNA 
polymerase (6cycles) and NEBnext multiplex oligos set 1 (NEB). Samples were purified 
using AMPure XP beads (1:1 ratio) and sequenced on one lane of HiSeq2500 (high 
output mode, 50bp single-end reads). UMI and gRNA sequences were extracted from 
individual reads by searching for exact matches to the vector backbone sequence at 
expected offsets (more than 76% of all reads). About 95% of extracted gRNA sequences 
corresponded to one of the expected sequences from the gRNA library 4, and the number 
of UMIs was counted for each gRNA. Counts of UMIs were 2.8 to 7.7-fold lower than 
read counts, indicating a low to moderate level of PCR duplication. As read versus UMI 
counts displayed a linear relationship, no correction for saturation of highly abundant 
gRNAs was applied. gRNAs with at least one non-zero count in any sample were selected 
for further analysis (84,471 gRNAs, 96.6% of the library). Counts from individual 
replicates for each of the six libraries (2 input, 4 experimental) were summed and 
analyzed by MAGeCK (version 0.5.4) 5 using parameters “--norm-method total --gene-
test-fdr-threshold 0.25 --adjust-method fdr --sort-criteria pos --remove-zero none” to 
identify gRNAs and genes significantly enriched in the experimental compared to the 
input libraries. 
 
Genome editing 
For C-terminal 3xFLAG Flcn tagging, the TALEN was assembled using Golden Gate 
TALEN cloning kit 6 (Addgene plasmid 1000000024) into acceptor vectors SV40-ELD 
and SV40-KKR 7 (FlcnC_F-Q3ELD: HD HD NN NI NI NN HD HD HD HD NI HD NI 
NN HD NG, FlcnC_R-Q3KKR: HD HD NI NN NI NI NN NN NI NN NG NG HD NG 
HD NN NN NI NN NG). E14 ESCs were transiently transfected with a recombination 
reporter 7, TALENs and Flcn tagging template 
(gtccaccgtccgaagccccacagctacagagtcacggagcGACTACAAAGACCATGACGGTGATT
ATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGtgactccgagaactcc
ttctggaaggtggtgtacagacca) and derivative clones were genotype for successful 
recombination. CRISPR/Cas9 genome editing was performed by transient transfection 
of hCas9 and U6-gRNA plasmids 8 (Addgene plasmids 41815 and 41824) into male 
RGd2 ESCs. Target gRNA sequences are detailed in Supplementary Table 4. For KO 
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ESC clone generation, a dsRed expression plasmid was cotransfected and single dsRed 
expressing cells were deposited into 96well plates 2d later. For screen validation, 
transfected cell pools were differentiated by 2i withdrawal after 2d and serially passaged 
in N2B27, 1µg/ml Blasticidin. 
 
Molecular biology 
Coding sequences were cloned from ESC cDNA and recombined into pDONR221 using 
Gateway technology (Invitrogen). The Lamtor1 LTS (amino acids 1-39) was inserted by 
In-Fusion cloning (Clontech) and point mutations (Rag-GDP (RagB: T54N, RagC: 
S75N, RagD: S77L), Rag-GTP (RagB: Q99L, RagC:Q120L, RagD:Q121L), otherwise 
indicated) were introduced by polymerase chain reaction. In Tfe3(10xA), 
S545,S550,S551,S553,S557,S560,S561,S564,S565 and S567 are mutated to alanine 
residues. Expression destination vectors were pPB-CAG-DEST-pgk-hph 2, pPB-TRE-
DEST-rTA-HSV-neo and pPB-TRE-DEST-rTA-pgk-hph. Gene expression analysis was 
performed using Trizol (Thermo Fisher) RNA extraction, SuperScriptIII (Invitrogen) and 
TaqMan Universal Master Mix (Applied Biosystem) with the Universal Probe Library 
(UPL, Roche). An endogenous control (GAPDH, Applied Biosystems) was used for 
normalizing expression. Primers and UPL probes are detailed in Supplementary Table 4. 
 
Protein methods 
Immunoprecipitations using Tfe3 antibodies of three biological replicates of Tfe3.7, 
LT1.3 and wildtype empty vector control ESCs, and Tfe3KO.6, LT1 KO.1, Flcn KO.1 
and wildtype ESCs expressing RagC-GDP and RagD-GDP were performed as described 
before 2 using DynaBeads (ThermoFisher). Proteins were digested on the beads first with 
0.2µg LysC (WAKO) for 6h at 37°C in 2.5M Guanidin-HCl, containing 20mM EPPS 
pH8.5, 10mM CAA and 5mM TCEP in a total volume of 6ul.  Then, samples were diluted 
with 18ul 50mM HEPES pH 8.5 containing 0.2µg modified porcine Trypsin (Promega) 
and cleaved overnight at 37°C. Another 0.2µg Trypsin was added and the cleavage was 
continued for 4 hours. The generated peptides were acidified with 1µl of 20% TFA and 
analyzed by capillary liquid chromatography tandem mass spectrometry with an EASY-
nLC 1000 using the two column set up (Thermo Scientific).  The peptides were loaded 
with 0.1% formic acid, 2% acetonitrile in H2O onto a peptide trap (Acclaim PepMap 
100, 75um x 2cm, C18, 3µm, 100Å) at a constant pressure of 800 bar. Peptides were 
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separated, at a flow rate of 150 nl/min with a linear gradient of 2–6% buffer B in buffer 
A in 3 minutes followed by an linear increase from 6 to 22% in 40 minutes, 22-28% in 9 
min, 28-36% in 8min, 36-80% in 1 min and the column was finally washed for 14 min at 
80% B (Buffer A: 0.1% formic acid, buffer B: 0.1% formic acid in acetonitrile) on a 
50um x 15cm ES801 C18, 2µm, 100Å column mounted on a DPV ion source (New 
Objective) connected to a Orbitrap Fusion (Thermo Scientific). The data were acquired 
using 120000 resolution for the peptide measurements in the Orbitrap and a top T (3s) 
method with HCD fragmentation for each precursor and fragment measurement in the 
LTQ according the recommendation of the manufacturer (Thermo Scientific). 
Protein identification and relative quantification of the proteins was done with MaxQuant 
version 1.5.3.8 using Andromeda as search engine 9 and label free quantification 10 as 
described in11. The mouse subset of the UniProt version 2015_01 combined with the 
contaminant DB from MaxQuant was searched and the protein and peptide FDR were 
set to 0.01. Only proteins identified with at least three peptides were plotted in Fig. 3g 
and h. Cell lysates for Western blotting were generated in RIPA buffer (50 mM Tris, pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1% Tx-100, 0.1% SDS). Primary antibodies were 
4EBP1 (Cell Signaling, 9452S, 1:100), S6 (Cell Signaling, 2217, 1:100), S6K1 (Cell 
Signaling, 9202S, 1:100), pS6 (S235/236) (Cell Signaling, 2211, 1:100), p4EBP1 (S65) 
(Cell Signaling, 13443S, 1:100) and pS6K1 (T389) (Cell Signaling, 9205, 1:100). 
 
Microarray data analysis 
Raw data (CEL files) were downloaded (all publically available sequencing data used 
in this study are indicated in Supplementary Table 4), background corrected and 
normalized using the rma function from the Bioconductor package oligo 12 (package 
version 1.40.0). A single probeset was selected per gene using annotation from the 
Bioconductor package mouse4302.db (package version 3.2.3), selecting the probeset 
with the largest interquartile range for each gene. Differentially expressed genes 
between Myc inhibition and DMSO samples were identified using the Bioconductor 
package limma 13 (package version 3.32.0) with default parameters. Genes were 
considered as significantly deregulated with a minimum absolute fold-change of 2 and 
a p-value smaller than 0.01. 
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Next generation sequencing data analysis 
Cellular RNA from ESCs, cells 34h after 2i withdrawal, and long-term differentiated 
cells sorted for Rex1 expression was purified using RNAeasy (Qiagen), strand-specific 
RNA-seq libraries were generated using TruSeq mRNA Library preparation kit 
(Illumina), and libraries sequenced on an Illumina HiSeq2500 machine (50bp single-
end reads). Reads were aligned using qAlign from the Bioconductor package QuasR 14 
(package version 1.16.0) to mouse GRCm38/mm10 genome with default parameters 
except for splicedAlignment=TRUE, which performs spliced alignments by internally 
running SpliceMap 15. EpiLC data were sequenced as 36bp reads 16, and therefore no 
spliced alignment could be performed. For in vivo embryo data 17 pre-existing 
alignments to mouse GRCm38/mm10 genome downloaded from ArrayExpress (E-
MTAB-2958) were used. Alignments were quantified with qCount from the 
Bioconductor package QuasR 14 (package version 1.16.0) for known UCSC genes 
obtained from the TxDb.Mmusculus.UCSC.mm10.knownGene package (package 
version 3.4.0) using default parameters (Supplementary Table 1). 
For identification of genes specifically regulated in either ESCs or during 
differentiation, we used generalized linear models. Only genes with at least 3 counts per 
million in at least two biological samples were considered (ESCs: 12,478 genes; 
differentiation: 12,709 genes). Statistically significantly deregulated genes were 
identified using edgeR 18 (package version 3.18.0) and these genes were fitted to five 
separate generalized linear models for different sets of samples: 
a) ~ genotype: Flcn KO or LT1 KO ESCs compared to respective control Flcn.6 and 
LT1.3 ESCs. 
b) ~ treatment: 3h Tam or 34h Tam-treated Tfe3-ERT2 ESCs compared to 3h or 34h 
ethanol-treated Tfe3-ERT2 ESCs. 
c) ~ time: Flcn.6 and Ethanol-treated Tfe3-ERT2 ESCs and 34h differentiated 
progeny 
d) ~ time + treatment: 34h Tam-treated differentiated Tfe3-ERT2 cells compared to 
ethanol-treated Tfe3-ERT2 ESCs and 34h differentiated progeny. treatment therefore 
identifies differentiation-specific nuclear Tfe3 targets. 
e) ~time + genotype + time:genotype: Flcn KO.1 ESCs and differentiated progeny 
compared to Flcn.6 ESCs and differentiated progeny. time:genotype therefore identifies 
differentiation-specific Flcn targets. 
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Raw P values were corrected for multiple testing by calculating false discovery rates 
(FDR) 19. Significant effects in each contrast were defined as changes with a minimum 
absolute fold-change of 2 and a FDR less than 0.01.  
For visualization in Fig. 2a, calculations of RNA log2 fold changes from edgeR were 
used and only significantly deregulated genes in at least one ESC condition (genotype, 
model (a) and treatment, model (b)) were considered (total: 2,483 genes). For 
visualization in Fig. 2c, significantly deregulated genes in at least one differentiation 
condition (time, model (c), treatment, model (d) and time:genotype, model (e)) were 
considered (total: 3,370 genes). Read counts were normalized (dividing by the total 
number of aligned reads and multiplying with minimal library size, and adding a 
pseudocount of 8) and log2 transformed. Centred expression values were generated by 
calculating differences in log-space of each gene in each sample to its average over all 
samples. For log2 fold change comparisons shown in Extended	Data	Fig.	2a, c and e, 
ESC genes detected in this study (12,478 genes) and annotated in other datasets (total: 
11,770 genes) were considered. For the pairwise comparison shown in Extended	Data	
Fig.	2f, only differentiation genes detected in this study (12,709 genes) and annotated in 
other datasets (total: 12,698 genes) were considered. Log2 fold changes were calculated 
using log2-transformed normalized read counts as described above, averaging 
biological replicates, and calculating differences (corresponding to fold-changes in 
linear space) between conditions. Analyses of enriched gene sets (Fig. 2c, Extended	
Data	Fig. 2b and e) were performed using DAVID for GO terms of biological 
processes, cellular components and molecular functions 20,21. Principal component 
analysis (Fig. 2b) was performed on normalized, log2-transformed and mean-centred 
expression data in R using the prcomp function. 
 
ChIP-seq data analysis 
Reads (Supplementary Table 1) were aligned using qAlign from the Bioconductor 
package QuasR 14 (package version 1.16.0) to mouse GRCm38/mm10 genome with 
default parameters. A set of non-redundant transcription start sites was created by 
randomly selecting for each gene a single start site. For meta-gene profiles, reads of 1kb 
up- and downstream for non-redundant transcription start sites were counted using 
qProfile from the Bioconductor package QuasR 14 (package version 1.16.0). The average 
profiles for statistically significantly upregulated genes in ESCs (3h Tam: 368 genes; 34h 
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Tam: 1,131 genes; Flcn KO: 420 genes; LT1 KO: 622 genes) as well as for a set of non-
significantly changing genes (absolute log2 fold-changes <1; P Value: >0.1; ns: 1,882 
genes) were plotted. 
 
Patients 
The study ascertained five affected individuals and their healthy parents. We obtained 
written informed consent from all subjects or their legal representatives. Genomic DNA 
from fresh skin, cultured skin fibroblasts, and blood samples was extracted using the 
Gentra Puregene Blood and Tissue Extraction Kit (Qiagen). Genomic DNA integrity and 
quantity was assessed by agarose gel electrophoresis, NanoDrop spectrophotometry, and 
Qubit fluorometry (Thermo Fisher). 
 
Whole exome sequencing (WES) 
We performed 26 trios WES on patient’s affected skin-derived DNA and parental blood 
sample. Exome capture and sequencing for patients 1, 2 and 5 were performed at 
Integragen (Evry, 209 France) from 1 µg of genomic DNA per individual using the 
Agilent SureSelect Human All Exon V5. Libraries were sequenced on a HiSeq platform 
(Illumina) using paired-end 75-bp reads. Sequences were aligned to the human genome 
reference sequence (GRCh37/hg19 212 build of UCSC Genome Browser), and single-
nucleotide variants and small insertions/deletions were systematically detected as 
previously described 22. Candidate de novo mutational events were identified by focusing 
on protein-altering and splice-site changes: (1) supported by at least three reads and 10% 
of total reads in the patient; (2) absent in both parents, as defined by variant reads 
representing less than 5% of total reads; (3) at base-pair positions covered by at least four 
reads in the entire trio; and (4) present at a frequency less than 1% in dbSNP (build 147) 
and 0.1% in the Exome Aggregation Consortium (ExAC Browser, 
exac.broadinstitute.org).  
WES for Patient 3 was enriched using the SureSelect XT Human All Exon V6 kit 
(Agilent) and sequenced (paired end 150bp) on a NextSeq500 sequencing system 
(Illumina) at a mean exome depth of 120X. The exome was defined as all coding exons 
of UCSC and Ensembl +/- 20bp intron flanks. This coverage was >99,5% for known 
intellectual disability genes, and 96.3% of the exome was covered at least 15X. Reads 
were aligned to hg19 using BWA (BWA-MEM v0.7.5a) and variants were called using 
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the GATK haplotype caller (v3.4.46). Detected variants were annotated, filtered and 
prioritized using the Bench NGS Lab platform (Cartagenia, Leuven, Belgium), and 
confirmed by Sanger sequencing. 
 
TFE3 sequencing 
Regions of interest were amplified using custom intronic primers and long-range 
polymerase chain reactions with the PrimeSTAR GXL DNA Polymerase (Takara Bio, 
Saint-Germain-en-Laye, France). Polymerase chain reaction amplicons were pooled, 
purified, and quantified from each affected individual. Sequencing libraries were 
prepared using the Nextera XT DNA Sample Preparation kit (Illumina, Paris, France). 
Paired-end sequencing of 150-bp reads was performed on a MiSeq platform using 300-
cycle reagent kits (v2; Illumina, Paris, France). 
 
Complementary DNA analysis 
Complementary DNA was sequenced from the first patient’s fresh skin, and second and 
fifth patient’s fibroblasts. Total RNA was isolated with TRIzol Reagent (Life 
Technologies) from fibroblasts, according to the manufacturer’s instructions. 1µg RNA 
was transcribed into cDNA with the QuantiTect Reverse Transcription Kit (Qiagen). 
Using PCR primers positioned in exons 2 and 6 in TFE3 gene, complementary DNA was 
amplified by polymerase chain reaction (PCR) using Prime STAR GXL kit (Takara) 
according to the manufacturer’s protocol. The libraries were prepared with the Nextera 
XT DNA Sample Preparation Kit (Illumina). Generated libraries were sequenced on a 
MiSeq instrument (Illumina) according to the manufacturer’s recommendations for 
paired-end 150 bp reads. 
 
Determination of the X-chromosome inactivation pattern at the HUMARA locus  
X-chromosome inactivation (XCI) pattern was estimated at the HUMARA locus as 
described previously 22 on DNA extracted from uncultured fibroblasts. Fluorescent PCR 
products were analyzed by capillary electrophoresis on an ABI3130XL genetic analyzer 
(Applied Biosystems) and peak areas were generated with the GeneMapper software 
(Applied Biosystems).  Skewing was defined as greater than 80% of one X allele active. 
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5	Addendum			The	 main	 results	 are	 presented	 in	 the	 manuscript	 submitted	 for	 publication.	Additional	 data	 acquired	 during	my	 PhD	 project	 besides	 the	manuscript	will	 be	documented	within	the	following	part.		5.1	 A	 genome-wide	 genetic	 screen	 has	 identified	 components	 of	 the	amino-acid	sensing	required	for	ESC	differentiation	
Exit	from	self-renewal	in	ESC	can	be	induced	in	vitro	by	the	removal	of	the	2i	and	is	followed	 by	 the	 initiation	 of	 differentiation.	We	 have	 performed	 a	 genome-wide	loss-of-function	(LOF)	screen	that	has	recovered	genes	previously	identified	in	the	pluripotency	 network	 (e.g.	 Tcf3)	 serving	 as	 a	 positive	 control.	 Importantly,	 the	screen	recapitulated	previous	finding	that	Folliculin	(Flcn)	is	key	for	the	exit	of	self-renewal	state	(Betschinger	et	al.,	2013).	Interestingly,	among	the	validated	hits,	we	could	find	four	out	of	the	five	Lamtor	proteins	that	constitute	the	ragulator	protein	complex,	a	principal	component	of	the	amino-acid	sensing	machinery	(Sancak	and	Sabatini,	2009).	However,	this	pathway	requires	several	additional	proteins	that	we	did	not	identify	in	the	screen	such	as	GATOR	proteins.	Lysosomal	recruitment	of	GATOR	through	KICSTOR	protein	complex		regulates	the	activity	of	the	Rag	GTPases	in	the	amino-acid	sensing	machinery	 (Wolfson	et	al.,	2017).	To	 test	 the	 importance	of	GATOR	complex	for	ESC	differentiation,	we	depleted	the	GATOR1	and	GATOR2	sub-units,	Depdc5	and	Mios	 respectively,	by	siRNA	knockdown.	To	assess	 the	 role	of	 these	proteins	in	ESC	differentiation,	we	compared	the	strength	of	differentiation	defect	upon	 knockdown	 of	 the	 selected	 genes	 by	 measuring	 the	 resistance	 to	differentiation	(Fig.	5).	Whereas	the	knockdown	of	Flcn,	Ragulator	subunits	and	Rag	GTPases	compromised	the	differentiation	efficiency,	the	downregulation	of	Depdc5,	Mios5	and	mTOR	had	no	effect	on	ESCs	differentiation.	This	supports	the	global	screen	findings	that	some	components	of	the	amino-acid	sensing	mechanism	play	 a	 role	 in	 the	 exit	 from	pluripotency,	 but	 not	 the	 entire	pathway.	
72	
		
	
	
Figure	5:	Loss	of	ragulator	and	Rag	C/D	GTPases	impair	ESC	differentiation	Resistance	to	differentiation	of	Oct4GIP	ESCs	transfected	with	indicated	siRNA	combinations	after	3	days	 of	 2i	 withdrawal.	 Results	 were	 normalized	 to	 negative	 siRNA	 cells.	 Average	 and	 standard	deviation	of	2	technical	replicates.		5.2	Flcn	is	recruited	to	the	lysosome	upon	starvation	in	ESCs	Although	Flcn	was	shown	 to	be	essential	 for	developmental	progression,	 little	 is	known	 about	 its	 molecular	 function	 in	 the	 control	 of	 ESC	 differentiation		(Betschinger	 et	 al.,	 2013);	 (Baba	 et	 al.,	 2006).	 Flcn	 has	 been	 reported	 to	 be	 a	cytoplasmic	 protein,	 recruited	 to	 the	 lysosome	 membrane	 upon	 amino-acid	starvation	(Tsun	et	al.,	2013);	(Petit	et	al.,	2013);	(Péli-Gulli	et	al.,	2015).	In	order	to	elucidate	 Flcn	 function	 in	 ESCs,	 we	 sought	 to	 gain	 mechanistic	 insights	 into	 its	action.	Because	of	the	lack	of	Flcn	antibody	compatible	with	immunofluorescence	techniques,	we	generated	a	functional	Flag-tagged	Flcn	allele	in	ESC	by	using	TALEN	genome	editing	system.	Since	the	absence	of	functional	Flcn	protein	leads	to	nuclear	accumulation	of	Tfe3,	we	verified	 that	 the	 subcellular	 localization	of	Tfe3	 in	 the	Flag-Flcn-knock-in	 ESCs	 was	 the	 same	 as	 in	 the	 WT	 cells	 (data	 not	 shown).	Immunofluorescence	 analysis	 of	 the	 endogenously	 tagged	 protein	 revealed	 that	Flcn	 is	 mainly	 distributed	 in	 the	 cytoplasm	 (see	 manuscript,	 Fig.	 3a).	 To	 test	whether	 the	 lysosomal	 recruitment	of	Flcn	 in	ESCs	also	occurs	 in	 an	amino-acid	dependent	manner,	 nutrient	 starvation	was	 induced	 by	 amino-acids	withdrawal	from	 the	 culture	 conditions.	 After	 starvation	 for	 50	 minutes,	 we	 could	 observe	colocalization	of	Flcn	and	 the	 lysosomal	protein	marker	Lamp1	(Fig.6).	Upon	re-addition	of	amino-acids	in	the	medium,	Flcn	appeared	released	from	the	lysosome	
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and	became	evenly	distributed	within	the	cytoplasm.	These	observations	indicate	that	Flcn	is	recruited	to	the	lysosome	upon	nutrient	starvation	in	ESC,	as	it	has	been	reported	for	other	mammalian	cell	lines	(Petit	et	al.,	2013)	(Tsun	et	al.,	2013).			
	
Figure	 6:	 Flcn	 recruitment	 to	 the	 lysosome	 in	 ESC	 occurs	 in	 response	 to	 amino-acid	
starvation		Immunofluorescence	staining	during	amino-acid	(AA)	starvation.	Upon	AA	withdrawal	for	50	minutes,	Flcn	colocalizes	with	the	lysosomal	protein	Lamp1.	Starved	ESCs	refed	with	AA	for	10	minutes	show	an	even	distribution	of	Flcn	in	the	cytoplasm.				5.3	Flcn	interacts	with	Fnip1/2	as	well	as	Gabarap	in	ESCs	Flcn	has	two	described	interacting	partners,	Fnip1	and	Fnip2	(Fnip1/2)	and	similar	to	 Flcn	 LOF,	 loss	 of	 Fnip1/2	 leads	 to	 differentiation	 block	 in	 ESCs.	 To	 identify	specific	molecular	partners	of	Flcn	in	ESCs,	we	made	use	of	the	Flcn	knock-in	ESC	line	 previously	 described.	 Flag-tagged	 immunoprecipitates	 of	 Flcn	 from	 cellular	lysates	of	ESCs	as	well	as	differentiated	cells	for	48	hours	were	analyzed	by	mass-spectrometry.	Similar	to	previous	findings	in	other	cell	types,	Flcn	interacted	with	Fnip1/2	(Fig.	7a).	Additionally,	we	identified	GABA(A)	receptor-associated	protein	(Gabarap)	as	an	interactor	of	Flcn	in	ESCs.	Gabarap	regulates	autophagy	and	binding	of	Gabarap	to	Flcn	is	regulated	by	the	autophagy	kinase	Ulk1	(Dunlop	et	al.,	2014).	Gabarap	and	Flcn	interaction	is	further	discussed	in	the	section	part	5.4.2.	To	identify	differential	binding	partners	of	Flcn,	we	sought	 to	 investigate	 if	 changes	 in	Flcn	 interactome	occur	 upon	 differentiation.	We	 compared	 the	 protein	 interactome	 of	 Flcn	 in	 the	pluripotent	 state	 and	 after	 two	 days	 of	 differentiation	 (Fig.	 7).	 Differential	
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comparison	of	both	 interactome	did	not	show	any	significant	changes	 in	binding	partners	of	Flcn.				
		
	
Figure	7:	Flcn	 interactome	and	differential	binding	between	2days	differentiated	cells	
and	ESCs	Label-free	quantitative	mass	spectrometry	analysis	of	Flag-immunoprecipitates	from	ESCs	(a)	and	differentiating	cells	(b).	Analysis	revealed	binding	of	Flcn	to	Fnip1	and	Fnip2,	and	Gabarap	with	no	differential	binding	between	ESC	and	differentiated	cells.	Quantification	 is	based	on	three	biological	replicates.			5.4	Metabolic	control	of	ESC	differentiation		
5.4.1	Nutrient	availability	controls	cell	fate	transition	in	ESCs		Our	previous	observations	from	the	screen	led	us	to	hypothesize	that	key	regulators	of	the	amino-acid	sensing	machinery	are	required	for	ESC	differentiation.	However,	whether	 this	 mechanism	 is	 functional	 in	 ESC	 remains	 to	 be	 determined.	 We	addressed	this	question	in	ESCs	by	performing	amino-acid	starvation	followed	by	amino-acid	stimulation	(Fig.	8).	As	a	read	out	we	measured	phosphorylation	levels	of	4EBP1,	a	direct	target	of	mTORC1,	since	it	has	been	shown	in	other	cell	types	that	mTORC1	 activity	 can	 be	 regulated	 by	 nutrient	 availability.	 After	 50	 minutes	 of	amino-acid	starvation,	mTORC1	activity	is	down-regulated	in	ESCs	while	it	gets	up-regulated	in	response	to	amino-	acid	stimulation	after	starvation	for	50	minutes.			
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Figure	8:	Amino-acid	starvation	in	ESCs	down-regulates	mTORC1	activity	Western-blot	analysis.	Amino-acid	(AA)	starvation	for	50	minutes	induces	down-regulation	of	mTORC1	activity	as	seen	by	the	reduced	phosphorylation	level	of	the	mTORC1	target	4EBP1.	AA	stimulation	after	starvation	re-activate	mTORC1	activity.					Although	ESC	differentiation	does	not	involve	any	nutrients	alterations,	we	sought	to	 investigate	 if	 amino-acids	 act	 in	 the	 control	 of	 ESC	 differentiation.	 To	 find	whether	a	single	or	a	group	of	amino-acids	is	particularly	involved	in	the	control	of	ESC	differentiation,	we	tested	if	its	omission	impairs	ESC	differentiation.	To	do	so	we	 developed	 a	 cell	 culture	medium	 based	 on	 the	 commercially	 available	 RPMI	medium	 called	 R-N2B27	 (RPMI	 based	 medium	 that	 recapitulates	 the	 N2B27	medium	usually	used)	 that	allows	 the	modulation	of	nutrient	composition.	Since	ESC	metabolism	depends	largely	on	glutamine	and	its	absence	does	not	impair	ESC	differentiation	 (data	 not	 showed),	 this	 amino-acid	was	 added	 to	 the	medium	by	default.	 As	 we	 have	 shown	 previously,	 amino-acid	 starvation	 in	 ESC	 promoted	nuclear	enrichment	of	Tfe3	and	impaired	differentiation	(see	manuscript,	extended	data	Fig.	4g-4h).	To	determine	 if	 differentiation	 impairment	occurs	upstream	of	 the	 transcription	factor	Tfe3,	we	conducted	the	experiment	in	parallel	in	WT	and	Tfe3	KO	ESCs.	Since	the	two	cell	lines	express	a	GFP	driven	by	pluripotency	reporter	gene	(Rex1),	we	monitored	decrease	of	GFP	intensity	by	flow	cytometry	as	a	measure	for	initiation	of	ESCs	differentiation.	Removal	of	essential	amino-	acids	(EAA)	or	non-essential	amino-	acids	(NEAA)	led	to	a	differentiation	defect	(Fig.	9a).	Removal	of	individual	amino-acids,	 essential	 or	 not,	 impaired	 differentiation,	 independently	 of	 Tfe3.	 A	representative	sample	is	shown	in	the	figure	bellow.							
76	
	
		
Figure	9:	Amino-	acid	starvation	impairs	ESC	differentiation	Flow	cytometry	profiles	of	WT	or	Tfe3	KO	Rex1GFPd2	ESCs.	Upon	differentiation,	GFP	intensity	decreases.	Pluripotent	ESCs	(blue)	and	differentiated	cells	for	24	hours	(red).	a)	In	the	RPMI	based	medium	(R-N2B27),	 in	presence	of	 essential	 and	non-essential	 amino-acids	 (EAA	and	NEAA,	 respectively),	 ESCs	 differentiate	 normally	 compared	 to	 the	 commercial	 medium	(N2B27).	Removal	of	the	EEA	or	the	NEAA	impairs	differentiation	of	WT	and	Tfe3	KO	ESCs.	b)	Removal	of	a	single	amino-acid	residue	impairs	differentiation	in	WT	and	Tfe3	KO	ESCs.				
5.4.2	Autophagy	is	not	required	for	the	exit	of	pluripotency		Cellular	stresses	like	starvation	often	lead	to	autophagy,	a	degradative	mechanism	ensuring	 cellular	 homeostasis	 and	 cell	 survival.	 Autophagy	 is	 principally	
a	
b	
77	
orchestrated	 by	 the	 lysosome,	 the	 key	 organelle	 that	 performs	 the	 enzymatic	digestion	 of	 endogenous	 macromolecules	 in	 order	 to	 generate	 elementary	molecules	 essential	 for	 the	 maintenance	 of	 basic	 anabolic	 reactions.	 We	 have	already	 addressed	 the	 role	 of	 the	 lysosome	 per	 se	 for	 ESCs	 differentiation	 (see	manuscript)	and	we	concluded	that	the	lysosomal	functions	are	required	upstream	of	the	nucleotide	loading	state	of	RagC/D	GTPase	and	Tfe3,	 in	order	to	drive	exit	from	pluripotency.	During	somatic	cell	reprogramming	into	pluripotent	stem	cell,	it	has	 been	 shown	 that	 autophagy	 is	 induced	 at	 an	 early	 stage	 in	 this	 process	(Mizushima	and	Levine,	2010).	In	line	with	acting	in	the	autophagy	pathway,	loss	of	Flcn	has	been	described	to	impair	autophagy	(Dunlop	et	al.,	2014).			Additionally,	 we	 have	 identified	 Gabarap	 as	 a	 Flcn	 interacting	 partner	 in	 ESCs.	Through	 its	 binding	 to	 Flcn,	 Gabarap	 regulates	 autophagy	 and	 the	 binding	 of	Gabarap	to	Flcn	is	regulated	by	the	autophagy	related	kinase	Ulk1	(Dunlop	et	al.,	2014).	The	transcription	factor	Tfeb,	another	MiTF	family	member,	has	also	been	implicated	in	the	regulation	of	autophagy	(Settembre	et	al.,	2012).		Based	on	these	observations,	we	tested	the	role	of	autophagy	in	the	exit	from	self-renewal	of	ESCs.	Down	regulation	of	key	genes	involved	in	autophagy	did	not	impair	ESC	 differentiation	 nor	 Tfe3	 subcellular	 localization	 therefore	 suggesting	 that	autophagy	is	not	required	for	the	exit	from	pluripotency	in	ESC	(Fig.	10).		 	
		
Figure	10:	Inactivation	of	autophagy	does	not	impair	ESC	differentiation		Resistance	to	differentiation	of	Oct4GIP	ESCs	transfected	with	indicated	siRNAs	after	3d	of	2i	withdrawal.	Results	were	normalized	 to	negative	siRNA	cells.	Average	and	SD	of	2	 technical	replicates.				
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5.4.3	mTORC1	activity	in	Flcn	and	Lamtor	1	KO	ESCs		In	our	loss	of	function	screen,	we	identified	genes	that	are	essential	for	ESC	exit	from	self-renewal	 upon	 long	 term	 exposure	 to	 differentiation	 stimuli.	 Some	 of	 these	genes	 have	 been	 described	 to	 act	 as	 activators	 or	 inhibitors	 of	 mTORC1	 in	 the	amino-	 acid	 sensing	 machinery	 (Fig.	 3).	 In	 addition,	 loss	 of	 function	 of	 Flcn,	Lamtor1,2	or	3,	and	by	extension	the	Ragulator,	decrease	mTORC1	activity.	Wether	these	findings	can	be	recapitulated	in	ESCs	remained	to	be	addressed.	We	further	investigated	mTORC1	activity	in	WT,	Flcn	and	Lamtor1	KO	ESCs,	as	well	as	upon	initiation	of	ESC	differentiation.	In	ESC	culture	conditions,	ESCs	display	a	low	basal	activity	of	mTORC1.	Neither	Flcn	nor	Lamtor1	KO	ESCs	showed	changes	of	mTORC1	activity	level	compared	to	WT	ESCs.	Interestingly,	upon	initiation	of	differentiation,	mTORC1	 activity	 increased	 in	WT	 ESC	 as	well	 as	 in	 Flcn	 and	 Lamtor1	 KO	 ESCs	despite	the	two	KO	lines	being	impaired	for	differentiation	(see	manuscript,	extend	data	Fig.	4f).	Since	the	differentiation	defect	of	Flcn	and	Lamtor1	KO	ESCs	can	be	rescued	by	expression	of	a	recombinant	version	of	RagC	GTPase	 in	a	GDP	bound	form,	we	aimed	to	determine	if	ESCs	overexpressing	RagC	preferentially	bound	to	GDP	 or	 GTP	 differentially	modulate	mTORC1	 activity.	 GDP	 and	 GTP	 nucleotide-bound	forms	of	RagC	have	been	described	as	active	and	inactive	form	in	regulating	mTORC1	activity,	respectively.	ESCs	expressing	RagC	preferentially	bound	to	GDP	or	GTP	displayed	similar	level	of	mTORC1	activity	compared	to	control	conditions	or	ESC	expressing	a	wild-type	RagC	transgene	(Fig.	11).	This	observation	therefore	suggests	an	alternative	mode	of	regulation	of	mTORC1	activity	in	ESC.			
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Figure	11:	RagC	GTPase	GDP	or	GTP	bound	form	do	not	regulate	mTORC1	activity	in	ESC	Western-blot	 analysis.	Over-expression	of	RagC	GTPase	 either	 bound	 to	GDP	or	GTP	do	not	increase	 mTORC1	 activity	 measured	 by	 phosphorylation	 level	 of	 the	 ribosomal	 protein	 S6.	Rapamycin	treatment	is	used	as	a	control	that	completely	inhibits	mTORC1	activity.				Additionally,	we	have	 investigated	mTORC1	localization	in	ESCs	expressing	RagC	GDP	or	GTP	bound	forms.	In	control	ESCs	expressing	an	empty	vector,	mTORC1	is	cytoplasmic	 although	 it	 colocalizes	 with	 the	 lysosomal	 marker	 Lamp1.	Overexpression	of	RagC	GDP	or	GTP	nucleotide	bound	form	does	not	lead	to	any	changes	in	mTORC1	localization.				
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Figure	12:	mTORC1	localization	in	ESCs	does	not	change	upon	expression	of	RagC	GDP	
nor	GTP	Immunofluorescence	staining.	Overexpression	of	Flag-RagC	is	confirmed	using	a	Flag	antibody.	Both	 RagC	 GDP	 and	 GTP	 colocalize	 with	 the	 lysosomal	 protein	 Lamp1.	 mTORC1	immunostaining	 do	 not	 display	 significant	 sub-cellular	 localization	 changes	 compared	 to	control	(empty).					
5.4.4	Hyper-activation	of	mTORC1	upon	Tsc2	LOF	impairs	ESC	differentiation,	
downstream	of	RagC/D	GTPases			Loss	 of	Tsc2	 in	ESC	 results	 in	 a	differentiation	defect	 accompanied	by	 a	nuclear	enrichment	 of	 the	 transcription	 factor	 Tfe3.	 In	 contrast	 to	 the	 loss	 of	 Flcn	 or	Lamtor1	in	ESCs,	Tsc2	LOF	phenotype	can	be	reverted	by	rapamycin	treatment	and	is	 consequently	 mTORC1	 dependent.	 Therefore,	 Tsc2	 KO	 ESCs	 lines	 have	 been	generated	where	an	mTORC1	upregulation	was	observed	(see	manuscript,	extend	data	Fig.	4i).	Studies	have	shown	that	Tsc2	mediated	mTORC1	regulation	via	Tsc2	occurs	via	lysosomal	recruitment	and	this	subcellular	localization	is	regulated	by	cellular	stresses	like	nutrient	starvation	(Demetriades	et	al.,	1AD).	Indeed,	mTORC1	needs	to	be	translocated	to	the	lysosome	where	it	gets	activated	by	Rheb	GTPase.	
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We	studied	mTORC1	localization	changes	upon	Tsc2	LOF	compared	to	WT	ESCs	by	immunofluorescence	 (Fig.	 13).	 Although	 Tsc2	 LOF	 strongly	 induces	 mTORC1	activity,	significant	changes	 in	mTORC1	localization	could	not	be	observed.	Since	overexpression	 of	 RagC	 GDP	 bound	 form	 reverted	 Tsc2	 LOF	 phenotypes,	 we	repeated	 the	 same	 immunofluorescence	 experiment	 in	 both	 cell	 lines.	Overexpression	 RagC	 GTPases	 in	 GDP	 or	 GTP	 nucleotide	 loading	 state	 did	 not	change	mTORC1	localization.			 	
		
Figure	13:	mTORC1	localization	 in	Tsc2	KO	ESCs	 is	unchanged	upon	RagC	GDP	or	GTP	
expression	Immunofluorescence	 staining.	 Overexpression	 of	 Flag-RagC	 in	 confirmed	 by	 using	 a	 Flag	antibody.	 Both	 RagC	 GDP	 and	 GTP	 colocalize	 with	 the	 lysosomal	 protein	 Lamp1.	 mTORC1	immunostaining	do	not	display	significant	 sub-cellular	 localization	changes	 in	Tsc2	KO	ESCs	compared	 to	 control	WT	ESCs	 (empty),	nor	upon	over-expression	of	any	of	 the	RagC	bound	form.				
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5.4.5	Tfe3	preferentially	binds	RagC	GDP	bound	form		Since	the	nucleotide	loading	state	of	RagC/D	controlled	by	Flcn	is	crucial	for	ESCs	differentiation,	we	sought	to	investigate	the	differential	binding	partners	of	RagC	GDP	and	RagC	GTP	bound	form.		We	aimed	 to	 identify	 the	differential	binding	partners	of	RagC	GTPases	whether	they	 are	 preferentially	 bound	 to	GDP	 or	GTP.	We	 found	 that	 Tfe3	 preferentially	binds	 RagC	 /D	 GTPases	 and	 this	 interaction	 was	 reported	 to	 localize	 at	 the	lysosomal	surface.	It	was	also	shown	that	the	binding	preferentially	occurs	when	Rag	 C/D	 is	 in	 the	 GDP	 bound	 form	 and	 we	 could	 confirm	 this	 finding	 by	immunoprecipitation	of	flag-tagged	RagC	transgenes	(GDP	or	GTP	bound	form)	and	by	confocal	microscopy.	Nevertheless,	this	interaction	might	be	transient	and	only	a	small	fraction	of	Tfe3	is	able	to	bind	RagC/D	GTPase	at	the	lysosome.	We	aimed	to	capture	 the	 transient	 interaction	 by	 inducing	 it	 while	 overexpressing	 Rag’s	GDP/GTP	bound	and	consequently	immunoprecipitated	endogenous	Tfe3	(Fig.	14).			
		
	
Figure	14:	Tfe3	preferentially	binds	RagC	GDP	bound	form	Tfe3	interactome	and	differential	binding	partners	of	cytoplasmic	and	nuclear	Tfe3.	On	the	x-axis	are	displayed	proteins	enriched	in	RagC-GDP	purifications	and	on	the	y-axis	the	ratio	of	binding	to	GDP	over	GTP	locked	RagC.	Known	RagC	interactors	are	recovered	including	the	Rag	heterodimer	as	well	as	Ragulator	subunits	without	significant	enrichment	 in	 the	GDP-bound	version.	In	contrast,	Tfe3	is	identified	as	specific	binding	protein	of	RagC	GDP.			
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5.5	Tfe3	sub-cellular	localization	dictates	ESC’s	fate		 In	 ESC,	 Tfe3	 is	 localized	 in	 both	 cytoplasmic	 and	 nuclear	 compartments.	 Upon	differentiation,	Tfe3	is	excluded	from	the	nucleus	and	remains	cytoplasmic.		We	aimed	to	understand	how	this	mechanism	is	regulated.	We	sought	to	identify	Tfe3	post-translational	modifications	as	well	as	specific	binding	partners	in	WT	and	Flcn	KO	ESCs.	We	made	use	of	an	inducible	tetracycline-controlled	transcriptional	activation	 (TetOn)	 system	 to	 express	 a	 Flag-tagged	 Tfe3	 transgene	 upon	Doxycycline	 (Dox)	 treatment	 (Fig.	 15a).	 This	 overexpression	 system	 allows	 for	enrichment	of	the	starting	material.	After	Dox	treatment	of	transfected	WT	and	Flcn	KO	 ESCs,	 expression	 of	 transgenic	 Tfe3	 was	 controlled	 by	 immunofluorescence	using	 a	 Flag	 antibody.	 The	 observed	 subcellular	 localization	 of	 the	 transgenic	protein	 followed	 the	 distribution	 of	 endogenous	 Tfe3	 in	 the	 respective	 genetic	background	(Fig.	15b).	To	 further	 identify	 specific	 partners	 and	 differential	 post-translational	modifications	of	Tfe3	regulating	its	differential	subcellular	localization,	Flag-tagged	Tfe3	 immunoprecipitates	 were	 purified	 after	 48	 hours	 of	 Dox	 treatment	 and	analyzed	by	mass	spectrometry	(MS).			Although	Tfe3	interacting	partners	were	not	different	between	WT	and	Flcn	KO	ESC,	MS	 analysis	 allowed	 for	 the	 detection	 of	 differential	 post-translational	modifications.	Phosphorylation	of	 a	 serine	 residue	 in	position	320	 (P-S320)	was	significantly	enriched	when	Tfe3	was	immunoprecipitated	from	WT	ESCs.	P-S320	post-translational	modification	has	been	described	as	an	mTORC1	phosphorylation	target	 site,	 required	 for	 the	 binding	 with	 the	 cytoplasmic	 protein	 14-3-3.	Nevertheless,	this	phosphorylation	site	is	not	sufficient	to	explain	the	phenotype.				
84	
		
Figure	15:	Tfe3	serine	320	is	phosphorylated	in	the	cytoplasm	a)	schematic	of	 the	 inducible	Flag-tagged	Tfe3	transgene	b)	 immunofluorescence	using	a	Flg	antibody	shows	the	subcellular	localization	of	the	Tfe3	transgene	upon	doxycycline	treatment	in	 WT	 and	 Flcn	 KO	 ESCs	 c)	 peptide	 sequence	 coverage	 of	 the	 transgenic	 Tfe3	 after	 mass	spectrometry	 analysis	 d)	 peptide	 count	 intensity	 shows	 increased	 phosphorylation	 of	 the	Serine	residue	in	position	320	of	Tfe3	immunoprecipitated	from	WT	ESCs.				Because	of	possible	drawbacks	linked	to	this	artificial	system,	we	made	use	of	an	antibody	targeting	the	endogenous	Tfe3	protein	for	further	experiments	where	we	concluded	that	Tfe3	binds	preferentially	RagC/D	in	a	GDP	bound	conformation	(see	manuscript,	Fig.	3h).	We	further	hypothesized	that	the	Flcn-RagC-ragulator-Tfe3	axis	is	acting	in	parallel	with	the	TSC2-RagC-Tfe3	axis.	We	therefore	sought	to	investigate	the	differential	migration	profile	of	Tfe3	in	TSC2	KO	ESCs	compared	to	WT	ESCs,	as	well	as	upon	over	expression	of	RagC/D	GDP	or	GTP	bound	form	in	both	genetic	backgrounds.	As	we	 previously	 described,	 Tfe3	 preferentially	 interacts	 with	 RagC/D-GDP	 bound	form.	Nevertheless,	we	could	not	observe	any	difference	in	the	migration	profile	of	Tfe3	between	the	immunoprecipitates	from	WT	or	TSC2	KO	ESCs.	Even	though	Tfe3	is	nuclear	in	TSC2	KO	ESCs,	the	migration	profile	of	Tfe3	in	the	input	fraction	is	unchanged	compared	to	WT	ESCs	(Fig.	16).	Upon	overexpression	of	Rag	C/D	GDP	bound	form,	we	observed	the	same	migration	profile	as	for	WT	ESCs	expressing	the	same	recombinant	protein.					
a	
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Figure	16:	Tfe3	binds	RagC/D	GDP	in	WT	and	Tsc2	KO	ESCs	Western	blot	analysis	of	Tfe3	immunoprecipitates	from	WT	ESCs	(upper	part)	and	Tsc2	KO	ESCs	(lower	part).	In	both	genetic	background,	Tfe3	migration	pattern	display	2	bands	on	the	WB;	a	fast	migrating	band	and	a	higher	band	(empty	vector	line).	Over-expression	of	RagC/D	GTPases	in	GDP	bound	form	induces	Tfe3	binding	in	WT	and	TSC2	KO	ESCs.				
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6	General	discussion	and	conclusions		 Cell	fate	transition,	or	how	a	cell	type	A	undergoes	a	series	of	changes	to	become	a	cell	type	B,	has	been	one	of	the	greatest	interest	in	developmental	biology	over	the	last	decade.	A	perfect	model	suited	to	address	cell	fate	transition	related	questions	are	embryonic	 stem	cells	 (ESCs)	 since	 they	are	pluripotent	and	can	differentiate	toward	all	the	lineages	as	in	vitro	differentiation	recapitulates	in	vivo	developmental	progression.	Previous	work	has	 identified	novel	genes	required	for	exit	 from	the	ESC	 state	 during	 differentiation	 (Betschinger	 et	 al.,	 2013),	 amongst	 others	identifying	 the	 tumor	 suppressor	 Folliculin	 (Flcn),	 acting	 upstream	 of	 the	transcription	factor	Tfe3.	Nevertheless,	 the	regulatory	framework	in	which	these	proteins	are	acting	in	ESCs	remains	unclear.			6.1	A	CRISPR/Cas9	screen	to	identify	novel	regulator	genes	acting	in	the	Flcn-Tfe3	pathway	
To	identify	novel	regulator	genes	acting	in	the	Flcn-Tfe3	pathway	and	controlling	exit	from	pluripotency,	we	screened	for	ESC	self-renewal	and	maintenance	of	the	pluripotency	 transcription	 factor	 Rex1	 in	 differentiation	 conditions	 using	 a	genome-wide	CRISPR/Cas9	gRNA	 library.	The	 specific	 goal	of	 this	 screen	was	 to	identify	genes	whose	lack	block	ESCs	differentiation	during	long-term	exposure	to	differentiation	stimuli.	Although	 the	biological	question	addressed	here	 is	 rather	similar	 to	previous	work	conducted	using	siRNA,	 the	 latter	had	 limitations	since	ESCs	 were	 transfected	 only	 transiently.	 In	 the	 present	 study,	 the	 CRISPR/Cas9	screen	offers	the	advantage	to	screen	for	genes	allowing	long-term	maintenance	of	pluripotency.	 The	 screen	 had	 successfully	 recovered	 the	 tumor	 suppressor	folliculin,	 which	 is	 associated	 with	 the	 Birt-Hogg-Dube	 (BHD)	 syndrome	 and	required	for	ESC	exit	from	pluripotency	upstream	of	the	cytoplasmic	inactivation	of	the	 basic	 helix-loop-helix	 (bHLH)	 transcription	 factor	 Tfe3	 (Betschinger	 et	 al.,	2013);	 (Hong	et	al.,	2010).	Of	 the	obtained	hits,	15	genes	whose	absence	 lead	 to	long-term	resistance	to	differentiation	were	validated	 in	a	secondary	screen	that	also	tested	for	ectopic	nuclear	localization	of	Tfe3	in	the	absence	of	each	of	the	15	
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genes.	This	has	identified	Flcn,	Lamtor1,2,4	and	5,	Tsc1	and	2,	and	also	recovered	gain-of	 function	 alleles	 of	 Tfe3	 itself.	 The	 small	 GTPase	 RagC	 belongs	 to	 the	validated	hit	of	the	genetic	screen	but	we	did	not	observe	obvious	changes	of	Tfe3	subcellular	localization	upon	RagC	loss	of	function.	However,	neither	RagA	or	B	nor	the	RagC	homologue	RagD	were	 identified	 in	the	screen.	Why	the	screen	did	not	identify	RagD	although	redundant	functions	with	RagC	remains	unclear.			6.2	Lamtor1	and	Flcn	knock-out	ESCs	are	pluripotent	and	impaired	for	differentiation	
Flcn	and	Lamtor1	null	embryos	show	embryonic	development	failure	around	the	gastrulation	stage,	consistent	with	being	important	for	ESC	differentiation	in	vitro	(Baba	et	al.,	2006);	(Nada	et	al.,	2009).	However,	their	role	in	ESCs	remains	poorly	understood.	 To	 get	 insights	 why	 Flcn	 and	 Lamtor1	 are	 be	 so	 crucial	 for	 ESC	differentiation,	 we	 generated	 the	 corresponding	 null	 ESC	 lines	 in	 an	 isogenic	background	 using	 gRNA	 targeting.	 Different	 genomic	 regions	 of	 each	 gene	were	targeted	and	two	independent	knock-out	(KO)	cell	lines	per	gene	were	generated.	Phenotypic	 characterization	 of	 the	 corresponding	 clones	 showed	 that	 Flcn	 and	Lamtor1	 loss-of-function	 (LOF)	 induced	a	 complete	differentiation	block	 in	ESCs	upon	2i	removal	as	well	as	in	the	EpiLC	inductive	differentiation	regime	(Fgf,	KSR	and	ActivinA).	We	therefore	concluded	that	Flcn	and	Lamtor1	KO	ESCs	are	not	able	to	exit	the	pluripotent	cell	state	which	is	consistent	with	the	developmental	arrest	observed	in	vivo	(see	manuscript	for	details).	To	further	study	the	role	of	Flcn	and	Lamtor1	during	early	development	progression,	additional	in	vivo	experiments	will	be	required.			6.3	 The	 tumor	 suppressor	 Flcn	 is	 required	 for	 ESC	 differentiation	upstream	of	RagC/D	GTPases	
Flcn	is	a	cytoplasmic	protein	that	can	be	recruited	to	the	lysosome	upon	amino-acid	starvation	 (see	 2.3.2	 and	 2.3.3).	 The	 literature	 suggests	 that	 Flcn	 meets	 and	
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activates	 RagC/D	 through	 its	 GTPase	 Activating	 Protein	 (GAP)	 activity	 at	 the	lysosome	(Tsun	et	al.,	2013);	(Petit	et	al.,	2013).	In	this	work,	we	have	shown	that	lysosomal	 RagC/D	 GDP	 is	 essential	 for	 ESC	 differentiation	 and	 the	 genetic	manipulations	suggest	that	it	is	mediated	through	the	GAP	activity	of	Flcn.	In	comparison	to	Lamtor1	KO	ESCs	that	can	escape	self-renewal	by	expression	of	a	RagC	transgene	targeted	to	the	lysosome	(LTS-RagC),	Flcn	KO	ESCs	failed	to	do	so.	It	suggests	that	the	differentiation	defect	observed	here	is	a	direct	consequence	of	the	absence	of	RagC/D	GDP	bound	form,	the	downstream	product	of	Flcn.	Indeed,	the	differentiation	defect	of	Flcn	KO	ESCs	could	be	bypassed	by	the	expression	of	a	RagC	transgene	locked	in	GDP	bound	conformation,	therefore	demonstrating	that	the	GAP	activity	of	Flcn	is	crucial	for	this	process.	Interestingly,	over	expression	of	RagC	 GDP	 leads	 to	 lysosomal	 enrichment	 of	 Tfe3.	 Surprisingly,	 LTS-RagC-GTP	dominantly	 induced	nuclear	Tfe3	localization	and	Tfe3-dependent	differentiation	impairment	in	wildtype	ESCs.	Taken	together	our	results	suggest	that	the	lysosomal	recruitment	of	RagC	serves	as	a	substrate	for	Flcn	GAP	activity	to	drive	cytoplasmic	sequestration	of	Tfe3	and	differentiation.	This	can	be	summarized	on	the	following	cartoon	(Fig.	17).		
	
	
Figure	 17:	 Lysosomal	 recruitment	 and	 nucleotide	 loading	 state	 of	 RagC/D	 GTPase	
downstream	of	Flcn	are	crucial	for	ESC	differentiation.	In	WT	ESC,	 the	ragulator	 is	 localized	at	 the	 lysosomal	compartment	and	allows	for	Flcn	GAP	activity.	 In	 Lamtor1	KO	ESC,	 absence	 of	 a	 functional	 ragulator	 leads	 to	 cytoplasmic	RagC/D	GTPases	and	impairs	ESC	commitment	upon	exposure	to	differentiation	stimuli.	Targeted	RagC	to	 the	 lysosome	 in	 this	 genetic	 background	 rescues	 differentiation	 impairment,	 presumably	because	Flcn	can	act	as	a	GAP.	In	Flcn	KO	ESCs,	the	ragulator	is	functional	but	RagC/D	is	locked	
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in	GTP	bound	form.	Targeted	RagC	in	GDP	bound	form	to	the	lysosome	rescues	differentiation	block	of	Flcn	KO	ESC.						In	the	context	of	amino-acid	sensing,	the	role	of	Flcn	is	not	yet	well	understood	and	it	might	 act	 in	 conveying	 a	metabolic	 related	 information	 from	 the	 extracellular	environment	 into	 the	 intracellular	milieu.	 However,	 it	 remains	 unclear	whether	Flcn	itself	acts	as	a	metabolic	sensor	in	the	amino-acid	sensing	machinery.	As	shown	in	other	cell	types,	Flcn	and	its	binding	partners	Fnip1	and	2	control	the	subcellular	distribution	of	 the	 transcription	 factor	Tfeb.	Flcn	deficient	ESCs	are	 impaired	 for	differentiation	and	exhibit	nuclear	enrichment	of	Tfe3.	Fnip1	interacts	with	the	C-terminal	 part	 of	 Flcn	 (Baba	 et	 al.,	 2006)	 and	 as	 Fnip1	 was	 recovered	 by	immunoprecipitation	of	endogenous	 flag-tagged	Flcn	 in	ESC,	 it	 indicates	 that	 the	Flag	 peptide	 added	 in	 C-terminal	 position	 of	 the	 Flcn	 genetic	 locus	 by	 TALEN	genome	 editing	 does	 not	 perturb	 the	 interaction	 with	 Fnip1.	 Further	 mass	spectrometry	analysis	of	 flag-tagged	Flcn	 immunoprecipitates	 in	ESCs	as	well	 as	after	two	days	of	differentiation	revealed	binding	of	Flcn	to	Fnip1	and	Fnip2.	The	interaction	with	Fnip1	has	been	reported	to	promote	interaction	with	the	nutrient	sensor	AMP-activated	Protein	Kinase	 (AMPK)	 that	 responds	 to	 low	nutrient	 and	energy	availability	leading	to	the	inhibition	of	mTORC1	(Baba	et	al.,	2006).	In	ESCs,	we	did	not	identify	any	interaction	between	Flcn	and	AMPK.	Consistent	with	a	previous	study,	we	have	found	in	ESCs	that	Gabarap	interacts	with	Flcn	and	consequently	tested	if	autophagy	pathway	is	involved	in	the	control	of	ESC	differentiation.	Knock	down	of	additional	genes	involved	in	the	autophagy	pathway	did	not	impair	ESC	differentiation	(Dunlop	et	al.,	2014).		It	 was	 shown	 in	 human	 cells	 that	 Lamtor3	 interacts	 with	 Flcn/Fnip2	 complex	(Rebsamen	 et	 al.,	 2015).	 However,	 we	 did	 not	 identify	 any	 interaction	 between	ragulator	sub-unit	and	Flcn.			Differential	 interactome	analysis	of	ESCs	compared	to	differentiated	cells	did	not	show	any	enrichment	of	state	specific	interactors	suggesting	that	Flcn	interactome	remains	unchanged	upon	differentiation.	To	investigate	the	role	of	Flcn	in	ESCs	and	specifically	 during	 the	 exit	 from	 pluripotency,	 we	 overexpressed	 different	 RagC	transgenes	(WT,	GDP	or	GTP	bound	form)	targeted	to	the	lysosome.	Here	we	aimed	to	 observe	 any	 changes	 in	 Flcn	 subcellular	 localization	 that	 would	 suggest	 a	
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preferential	binding	toward	a	specific	nucleotide	loading	state	of	RagC.	Using	our	experimental	 set	 up,	 we	 were	 not	 able	 to	 determine	 any	 significant	 changes.	Moreover,	 Flcn	 subcellular	 localization	 remains	 unchanged	 upon	 initiation	 of	differentiation.	In	fact,	mass	spectrometric	analysis	of	endogenous	flag-tagged	Flcn	did	not	 identify	any	post-translational	modification	that	could	explain	a	dynamic	activity	during	differentiation.		Additionally,	 immunoprecipitation	 of	 flag-tagged	 RagC	 GDP	 or	 GTP	 bound	 form	coupled	to	mass	spectrometry	analysis	revealed	that	the	transcription	factor	Tfe3	preferentially	binds	RagC	GDP	but	not	Flcn.	Hence,	the	role	of	Flcn	in	ESC	during	differentiation	remains	not	fully	understood.			6.4	Towards	an	alternate	lysosomal	signaling	pathway			Since	the	lysosomal	functions	per	se	have	never	been	reported	to	act	in	the	control	of	the	exit	from	pluripotency,	we	investigated	if	perturbation	of	lysosomal	activity	could	 affect	 ESC	 differentiation.	We	 have	 shown	 that	 perturbation	 of	 lysosomal	functions	impairs	ESC	differentiation	and	this	can	be	rescued	by	lysosomal	targeted	expression	 of	 RagC	 GDP.	 Interestingly,	 Tfe3	 LOF	 ESCs	 can	 differentiate	 in	 the	presence	of	drugs	perturbing	lysosomal	functions	(see	manuscript,	Fig.	3e	–	3f).	By	opposition	to	lysosomal	functions	that	are	required	for	cellular	survival,	we	have	assessed	 in	 the	 present	work	 the	 role	 of	 the	 lysosomal	 functions	 in	 the	 precise	framework	 that	 is	 the	 short	 time	window	of	 the	 exit	 from	 self-renewal	 in	 ESCs.	Whether	 lysosomal	 perturbations	 will	 affect	 the	 following	 steps	 of	 early	development	remain	to	beunderstood.		The	amino-acid	sensing	mechanism	is	orchestrated	at	the	lysosomal	compartment	and	lysosomal	functions	are	required	for	this	process	as	it	has	been	shown	that	the	lysosomal	V-ATPase	acts	as	a	GEF	for	Rag	GTPases	RagA/B	in	response	to	amino-acid	availability	within	 the	 lysosomal	 lumen.	This	 is	 important	 for	 the	 lysosomal	recruitment	and	activation	of	mTORC1	in	response	to	amino-acid	stimili.	In	ESCs,	this	pathway	might	not	be	strictly	identically	regulated	and	could	act	as	a	metabolic	checkpoint	 allowing	 ESCs	 to	 undergo	 differentiation,	 or	 not,	 since	 ESCs	differentiation	is	a	very	demanding	energetic	process	and	ESCs	have	to	make	sure	
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that	nutrients	are	available	for	a	proper	developmental	progression.	Consistent	with	the	ragulator	acting	 in	ESC	differentiation,	Lamtor3	protein,	also	called	MP1,	has	been	 identified	 in	a	genetic	screen	performed	by	using	siRNA	 in	ESCs	in	a	setup	addressing	another	biological	question	(Westerman	et	al.,	2011).	In	this	study,	the	authors	identified	Lamtor3	as	a	factor	important	for	differentiation.	At	that	time,	the	ragulator	was	not	yet	characterized	and	Lamtor	proteins	could	not	have	 been	 replaced	 in	 the	 lysosomal	 amino-acid	 sensing	machinery.	 This	 study	already	 provided	 evidence	 that	 the	 ragulator	 acts	 in	 the	 control	 of	 ESC	differentiation.	In	addition,	the	authors	showed	that	downregulation	of	Lamtor3	in	ESC	 affects	 the	 phosphorylation	 levels	 of	 Erk	 and	 therefore	 argued	 that	 the	differentiation	inhibitory	effect	of	knockdown	of	Lamtor3	is	not	likely	to	be	a	result	of	 total	 ablation	 of	 Erk	 signaling	 but	 rather	 a	 result	 of	 modulation	 of	 the	 Erk	signaling	network	that	 leads	to	ESC	differentiation.	These	 interpretations	 led	the	authors	 to	 hypothesize	 that	 the	 mechanism	 might	 occur	 through	 endosomal	signaling	since	Mp1	localizes	to	late	endosomes	in	ESCs.	Interestingly	and	in	line	with	 this	 hypothesis,	 Hgs,	 a	 component	 of	 the	 ESCRT-0	 complex	 that	 initiates	sorting	of	ubiquitinylated	receptors	into	the	multivesicular	body	pathway,	has	been	identified	 in	 a	 loss	 of	 function	 genetic	 screen	 as	 a	 gene	 required	 for	 ESC	differentiation	 (Betschinger	 et	 al.,	 2013).	 However,	 neither	 knockdown	 of	 the	facultative	ESCRT-0	Hgs	interactor	Stam	nor	selected	ESCRT-I,	-II	or	–III	subunits	impair	ESC	differentiation.	Although	we	did	not	find	Hgs	in	the	CRISPR/Cas9	screen,	this	 should	 be	 kept	 in	mind	 as	 an	 additional	 finding	 supporting	 the	 idea	 that	 a	lysosomal	pathway	contributes	to	exit	from	pluripotency.		We	 have	 shown	 that	 perturbation	 of	 lysosomal	 activity	 induced	 nuclear	 Tfe3	enrichment	and	RagC-GDP-	and	Tfe3-dependent	differentiation	defects,	suggesting	that	lysosomal	activity	controls	ESC	differentiation.		Together,	 our	data	 repurposed	a	 conserved	mechanism	of	 lysosomal	 amino-acid	sensing	that	plays	a	fundamental	role	during	early	developmental	stage.		
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6.5	Metabolic	control	of	ESC	pluripotency		
Metabolic	profiles	vary	from	one	cell	type	to	another	and	a	current	notion	in	the	literature	indicates	that	the	metabolic	switch	occurring	during	cell	fate	transition	is	probably	the	cause	and	not	the	consequence	of	this	process	(Shyh-Chang	and	Ng,	2017).	 As	 a	 metabolic	 shift	 has	 been	 described	 from	 oxidative	 phosphorylation	toward	 anaerobic	 glycolysis	 from	 the	 pre-	 to	 post-implantation	 epiblast	 ESCs,	 a	metabolic	 shift	 in	 the	 opposite	 direction	 has	 also	 been	 observed	 during	reprogramming	(Panopoulos	et	al.,	2011).	We	have	identified	the	lysosome	acting	in	 the	regulation	of	ESCs	differentiation	and	 in	addition	 to	previous	 findings,	we	describe	 this	degradative	organelle	as	an	 integrative	platform	that	regulates	and	secures	 developmental	 progression	 of	 ESCs	 in	 vitro.	 The	 lysosomal	 signaling	pathway	 is	 conceptually	 interesting	 since	 this	organelle	has	key	 functions	 in	 the	regulation	of	cellular	metabolic	reactions	and	 is	highly	 involved	 in	 the	control	of	cellular	growth.		The	 tumor	suppressor	Flcn	 is	required	 for	ESC	differentiation.	 In	 the	amino-acid	sensing	 pathway,	 Flcn	 is	 a	 GAP	 for	RagC/D	 and	 its	 recruitment	 to	 the	 lysosome	occurs	 during	 starvation	 conditions.	We	 hypothesized	 that	 Flcn	 is	 involved	 in	 a	pathway	that	links	metabolism	and	pluripotency.	This	hypothesis	suggests	that	Flcn	acts	as	a	sensor	in	this	pathway	and	cytoplasmic	localization	of	Flcn	is	secured	by	the	presence	of	a	signaling	molecule,	which,	upon	starvation,	should	not	be	longer	present	in	the	cytoplasm.	Although	such	molecule	has	not	been	identified	yet,	we	further	aimed	to	understand	if	amino-acids	have	a	role	in	the	control	of	ESC	differentiation.	We	observed	that	removal	of	essential	or	non-essential	amino-acids	impairs	exit	from	self-renewal	in	ESCs.	However,	we	did	not	specifically	investigate	if	amino-acid	starvation	impairs	cellular	proliferation.	If	so,	 it	 would	 suggest	 that	 starvation	 induces	 a	 proliferation	 defect,	 therefore	rendering	 ESCs	 insensitive	 to	 differentiation	 stimuli.	 While	 we	 were	 aiming	 to	differentiate	 ESCs	 under	 starvation	 stress	 condition,	 an	 interesting	 observation	occurred	 when	 only	 valine	 residue	 was	 omitted	 from	 the	 medium.	 Exclusive	omission	 of	 valine	 residue	 from	 the	 medium	 led	 to	 a	 complete	 inhibition	 of	proliferation	 associated	 with	 an	 important	 cell	 death	 (data	 not	 shown).	 This	observation	has	already	been	reported	for	both	human	and	murine	hematopoietic	
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stem	cells	where	valine	has	been	reported	to	be	essential	for	cellular	growth	(Taya	et	al.,	2016).	Removal	of	essential	amino-acids	induced	a	starvation	stress	response	accompanied	by	nuclear	Tfe3	enrichment	and	resistance	to	differentiation	in	ESCs.	Surprisingly,	we	could	observe	a	mild	rescue	upon	overexpression	of	LTS-RagC	GDP	during	starvation	(see	manuscript,	extend	data	Fig.	4h).	To	address	the	question	if	this	 rescue	 could	 be	 due	 to	 a	 possible	 effect	 of	 RagC-GDP	 over	 expression	 that	induces	a	priming-like	effect	 in	ESCs,	 further	 investigations	must	be	undertaken,	first	 by	 assessing	 the	 expression	 levels	 of	 pluripotency	 associated	 genes.	Nevertheless,	the	reversion	of	the	phenotype	was	not	recapitulated	in	Tfe3	KO	ESCs.		It	 should	 be	 kept	 in	mind	 that	 overexpression	 of	 any	 nucleotide	 bound	 form	 of	RagC/D	GTPase	does	not	regulate	mTORC1	activity	in	ESCs.	Other	studies	have	also	reported	that	expression	of	the	dominant	negative	forms	of	RagGTPases	(RagC/D-GTP)	abolishes	the	amino-acid	sensing	machinery	and	cells	expressing	RagC/D	GTP	remain	 insensitive	 to	 amino-acid	 stimulation	 following	 a	 starvation	 period	 and	display	Tfeb,	a	family	member	of	Tfe3,	exclusively	in	the	nucleus	(Settembre	et	al.,	2012).	Interestingly,	overexpression	of	LTS-RagC	GTP	in	ESCs	led	to	accumulation	of	Tfe3	in	the	nuclear	compartment	and	impaired	ESCs	differentiation,	downstream	of	Tfe3.		Finding	 a	 nutrient	 sensor	 components	 of	 the	 lysosomal	 pathway	 involving	 Flcn	should	 help	 to	 understand	 in	more	 details	 the	metabolic	 regulation	 of	 ESC	 self-renewal	upstream	of	Tfe3.	Our	work	illustrates	the	general	notion	present	in	the	literature	about	the	metabolic	control	of	cell	fate	transition	in	ESCs.	Indeed,	while	we	were	aiming	to	identify	if	amino-acid	starvation	impairs	ESC	differentiation,	we	could	not	identify	a	unique	amino-acid	whose	omission	impaired	differentiation	in	a	 Tfe3	 dependent	 manner.	 Taken	 together	 these	 observations	 suggest	 a	 Flcn-RagC/D-ragulator-Tfe3	dependent	mechanism	driving	ESC	differentiation.		6.6	mTOR	activity	is	not	required	for	ESCs	differentiation	
Studies	 have	 shown	 that	 deregulation	 of	mTOR	 activity	 often	 leads	 to	 dramatic	consequences	and	mTOR	activation	is	a	common	feature	of	diseases	as	seen	in	many	
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different	 types	 of	 cancer	 or	 neurological	 diseases.	 Therefore,	 understanding	 the	cause	of	these	deregulations	remains	an	outstanding	challenge.	While	 we	 were	 aiming	 to	 identify	 genes	 whose	 absence	 impairs	 ESCs	differentiation,	 we	 identified	 the	 tumor	 suppressor	 Flcn	 as	 well	 as	 the	 Lamtor	proteins	that	form	the	ragulator	protein	complex.	Together,	Flcn	and	the	ragulator	activate	 mTORC1	 in	 an	 amino-acid	 dependent	 manner	 in	 somatic	 cells.	Nevertheless,	we	have	shown	in	ESCs	that	mTORC1	activity	is	independent	of	Flcn	and	Lamtor1.	Additionally,	chemical	or	genetic	inhibition	of	mTORC1	in	ESCs	did	not	 induce	 differentiation	 defect	 nor	 nuclear	 Tfe3	 enrichment	 suggesting	 that	mTORC1	activity	 is	dispensable	 for	ESCs	differentiation.	Surprisingly,	 removal	of	the	 two	 inhibitors	 sustaining	 ESC	 pluripotency	 in	 vitro	 is	 accompanied	 by	 an	increase	of	mTORC1	activity	in	Flcn	and	Lamtor1	KO	ESCs	although	these	two	cell	lines	do	not	differentiate.	If	this	increased	mTORC1	activity	occurs	in	response	to	MAPK/Erk	signaling	pathway	activation	remains	to	be	determined.			Published	 transcriptomics	data	 from	mTOR-inhibited	ESCs	do	not	correlate	with	transcriptional	 alterations	 in	 Lamtor1	 and	 Flcn	KO	ESCs	 (Bulut-Karslioglu	 et	 al.,	2016).	 Interestingly,	 hyper-activation	 of	mTORC1	 upon	 loss	 of	 TSC2	 phenocopy	Flcn	loss	of	function	phenotypes	in	ESCs	and	feature	nuclear	Tfe3	localization.	This	phenotype	can	be	reverted	by	rapamycin	treatment	as	well	as	the	over	expression	of	RagC-GDP	or	Tfe3	LOF.		During	nutrient	starvation	in	somatic	cells,	mTORC1	activity	has	been	reported	to	be	downregulated.	We	could	also	confirm	this	finding	in	ESCs.	The	overexpression	of	RagC	GDP	bound	form	has	been	described	to	activate	mTORC1	activity	in	somatic	cells.	 However,	 it	 appears	 not	 to	 be	 the	 case	 in	 ESCs.	 This	 indicates	 a	 tuned	regulation	 of	mTORC1	 pathway	 that	might	 differ	 from	 one	 cell	 type	 to	 another,	suggesting	that	minor	alterations	of	this	pathway	lead	to	phenotypical	variations.	Although	 overexpression	 of	RagC	GDP	or	GTP	doesn’t	 perturb	mTORC1	 activity,	Tfe3	subcellular	localization	does	change	accordingly.	Forced	lysosomal	expression	of	Rag	GTP	redirect	Tfe3	to	the	nucleus	and	strongly	enhanced	the	maintenance	of	pluripotency.		The	Tfe/MiTF	transcription	factor	family	has	been	linked	to	metabolic	response	in	different	 cell	 types.	 In	 ESCs,	 the	 nucleocytoplasmic	 distribution	 of	 Tfe3	 coincide	
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with	what	has	been	reported	for	Tfeb.	Tfeb	has	been	shown	to	be	a	main	player	in	starvation	where	upon	starvation,	it	translocates	to	the	nucleus	(Settembre	et	al.,	2012);	(Settembre	et	al.,	2013).	In	addition,	nutrient	starvation	as	well	as	lysosomal	perturbations	induced	nuclear	translocation	of	Tfe3	in	ESCs	as	it	was	shown	to	be	the	case	in	other	somatic	cell	type.		Taken	 together,	 the	work	 presented	 here	 advances	 our	 knowledge	 about	 a	 new	route	 for	 the	 control	 of	 exit	 from	 pluripotency	 in	 ESC	 that	 takes	 place	 at	 the	lysosomal	compartment	and	provides	insight	into	the	metabolic	regulation	of	this	process.														
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